Sheffield Hallam University

The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019.

SANTOS, João Vasco, PADRON-MONEDERO, Alicia, BIKBOV, Boris, GRAD, Diana Alecsandra, PLASS, Dietrich, MECHILI, Enkeleint A, GAZZELLONI, Federica, FISCHER, Florian, SULO, Gerhard, NGWA, Che Henry, NOGUER-ZAMBRANO, Isabel, PEÑALVO, José L, HAAGSMA, Juanita A, KISSIMOVA-SKARBEK, Katarzyna, MONASTA, Lorenzo, GHITH, Nermin, SARMIENTO-SUAREZ, Rodrigo, HRZIC, Rok, HANEEF, Romana, O'CAOIMH, Rónán, CUSCHIERI, Sarah, MONDELLO, Stefania, KABIR, Zubair, GBD 2019 EU STATE OF HEALTH COLLABORATORS, FREITAS, Alberto and DEVLEESSCHAUWER, Brecht

Available from Sheffield Hallam University Research Archive (SHURA) at:

https://shura.shu.ac.uk/35459/

This document is the Published Version [VoR]

Citation:

SANTOS, João Vasco, PADRON-MONEDERO, Alicia, BIKBOV, Boris, GRAD, Diana Alecsandra, PLASS, Dietrich, MECHILI, Enkeleint A, GAZZELLONI, Federica, FISCHER, Florian, SULO, Gerhard, NGWA, Che Henry, NOGUER-ZAMBRANO, Isabel, PEÑALVO, José L, HAAGSMA, Juanita A, KISSIMOVA-SKARBEK, Katarzyna, MONASTA, Lorenzo, GHITH, Nermin, SARMIENTO-SUAREZ, Rodrigo, HRZIC, Rok, HANEEF, Romana, O'CAOIMH, Rónán, CUSCHIERI, Sarah, MONDELLO, Stefania, KABIR, Zubair, GBD 2019 EU STATE OF HEALTH COLLABORATORS, FREITAS, Alberto and DEVLEESSCHAUWER, Brecht (2024). The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019. BMC public health, 24 (1): 1374. [Article]

Copyright and re-use policy

Sheffield Hallam University Research Archive http://shura.shu.ac.uk See http://shura.shu.ac.uk/information.html

RESEARCH

Open Access



The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019

João Vasco Santos^{1,2,3*}, Alicia Padron-Monedero⁴, Boris Bikbov⁵, Diana Alecsandra Grad^{6,7}, Dietrich Plass⁸, Enkeleint A. Mechili^{9,10}, Federica Gazzelloni¹¹, Florian Fischer¹², Gerhard Sulo¹³, Che Henry Ngwa¹⁴, Isabel Noguer-Zambrano⁴, José L. Peñalvo¹⁵, Juanita A. Haagsma¹⁶, Katarzyna Kissimova-Skarbek¹⁷, Lorenzo Monasta¹⁸, Nermin Ghith¹⁹, Rodrigo Sarmiento-Suarez^{4,20}, Rok Hrzic²¹, Romana Haneef²², Rónán O'Caoimh^{23,24}, Sarah Cuschieri²⁵, Stefania Mondello²⁶, Zubair Kabir²⁷, GBD 2019 EU State of Health Collaborators, Alberto Freitas^{1,2} and Brecht Devleesschauwer^{28,29}

Abstract

Background The European Union (EU) faces many health-related challenges. Burden of diseases information and the resulting trends over time are essential for health planning. This paper reports estimates of disease burden in the EU and individual 27 EU countries in 2019, and compares them with those in 2010.

Methods We used the Global Burden of Disease 2019 study estimates and 95% uncertainty intervals for the whole EU and each country to evaluate age-standardised death, years of life lost (YLLs), years lived with disability (YLDs) and disability-adjusted life years (DALYs) rates for Level 2 causes, as well as life expectancy and healthy life expectancy (HALE).

Results In 2019, the age-standardised death and DALY rates in the EU were 465.8 deaths and 20,251.0 DALYs per 100,000 inhabitants, respectively. Between 2010 and 2019, there were significant decreases in age-standardised death and YLL rates across EU countries. However, YLD rates remained mainly unchanged. The largest decreases in age-standardised DALY rates were observed for "HIV/AIDS and sexually transmitted diseases" and "transport injuries" (each -19%). "Diabetes and kidney diseases" showed a significant increase for age-standardised DALY rates across the EU (3.5%). In addition, "mental disorders" showed an increasing age-standardised YLL rate (14.5%).

Conclusions There was a clear trend towards improvement in the overall health status of the EU but with differences between countries. EU health policymakers need to address the burden of diseases, paying specific attention to causes such as mental disorders. There are many opportunities for mutual learning among otherwise similar countries with different patterns of disease.

*Correspondence: João Vasco Santos jvasco.santos@gmail.com Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.gr/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.gr/licenses/by/4.0/.

Key-points

• This article, systematically analysing GBD 2019 study estimates, presents an overview of the state of health in the European Union in 2019, compared to 2010.

• There was an improvement in the overall health status of the EU, despite substantial differences between Member States.

• Cardiovascular diseases and neoplasms are the major contributors to the overall burden of diseases in the EU in 2019.

• The age-standardised rate of years lived with disability due to mental disorders has been increasing and is expected to increase even more because of the COVID-19 pandemic.

• This report provides a framework upon which to base further region- and country-specific health policies and interventions, to support health planning and priority setting.

Keywords European Union, Health status, Population health, Global Burden of Diseases, European Burden of Disease Network

Introduction

The European Union (EU) faces many challenges that impact current and future population health, including complex issues such as population ageing, digital and green transitions, socio-economic challenges and the organisation of health systems. In addition, there are still significant differences in health status between EU countries which are associated with factors such as structural and budgetary differences, variations in the effectiveness of public health policies and health related risk factors [1-6]. In fact, health systems differ across the EU and, for instance, while the 2008 global financial crisis reduced annual health budgets, this did not happen uniformly. In addition, as population ageing advances, multimorbidity and frailty are becoming more common and need to be addressed to improve the well-being of EU countries [7-9].

According to Eurostat, life expectancy at birth in the EU was 81.0 years in 2019, with women living, on average, 5.5 years longer than men [4, 10]. Beyond life expectancy, population health can be summarised through combined health metrics such as healthadjusted life expectancy (HALE) and disability-adjusted life years (DALYs). DALYs consist of two components: (i) years of life lost (YLLs), which captures health loss due to premature mortality, and (ii) years lived with disability (YLDs), which quantifies health loss due to morbidity. A previous study showed a decline in YLD and DALY rates, an increase in life expectancy of 5.9 years and an increase in HALE of 4.6 years, on average, from 1990 to 2017 among EU-28 countries [11]. However, another study concluded that, despite the improvement in the health status of the EU, several central and eastern European countries had not experienced such pronounced gains in overall health in comparison to the EU-15 [12].

Accurate and timely data on mortality and morbidity, caused by diseases and injuries and their trends over time are essential to assess the impact of health strategies and assist policy makers in improving health planning and priority setting. This information can also be used to understand between-region variations, providing opportunities for mutual learning among EU countries. The Global Burden of Disease (GBD) study generates estimates of population health using a wide range of metrics, capturing the impact of diseases, injuries and risk factors on health. Furthermore, it allows for comprehensive comparisons over time and across countries. Burden of disease estimates are increasingly used in the EU and globally, as they provide a comprehensive and comparable picture of the overall population health status. An earlier analysis of the results from the GBD 2017 study for the EU countries examined changes since 2007 for the burden of diseases and injuries in the EU-28 in 2017 [13]. Between the release of the GBD 2017 and the GBD 2019 datasets, several improvements were made, including key demographic modelling steps, preferred/ reference case definitions or measurement methods and the development of a Bayesian meta-regression tool, as well as the inclusion of more data sources and 12 new causes [14, 15].

In this paper, we analyse the GBD 2019 study estimates (focusing on deaths, YLDs, YLLs, DALYs, life expectancy and HALE) and compare the years 2019 and 2010 to describe the current health status of the EU. The aim of this study is to provide a picture of the state of health in the EU-27 countries in 2019, to examine how these have changed since 2010 and to highlight meaningful opportunities that exist to improve health across the continent.

Methods

Data source and overview of the GBD 2019 study

We obtained estimates from the 2019 GBD study for the EU-27 region and for the 27 EU countries individually. Considering the period of analysis, the 27 EU member states countries included were: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.

A detailed description of methods and results used in GBD 2019 has been published elsewhere [14-17]. In brief, the GBD 2019 study is a collaborative effort of more than 5,000 researchers, aiming to measure population health at global, regional and national levels by quantifying the burden of 369 diseases and injuries (i.e. 286 causes of death and 364 non-fatal causes) and 87 risk factors between 1990 and 2019 for 204 countries and territories. Several improvements were made in the GBD 2019 study, including key demographic modelling steps, reference case definitions or measurement methods and the Bayesian meta-regression tool. In addition, more data sources and 12 new causes were added to the GBD modelling framework, including pulmonary arterial hypertension, nine new sites of cancer, and two new sites of osteoarthritis (hand and other joints). The GBD produces estimates of incidence, prevalence, mortality, YLDs, YLLs, DALYs, life expectancy and HALE for the entire time span between 1990 and 2019. Cause-specific death rates and cause fractions are calculated using the Cause of Death Ensemble model (CODEm) and spatiotemporal Gaussian process regression. They are adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates [15, 18].

DALYs consist of two main components: YLLs and YLDs. YLLs are calculated by multiplying the number of deaths of each age the remaining life expectancy (RLE) at age of death derived from the GBD standard life Table [19]. YLDs are estimated by multiplying the prevalence counts by the disability weight for each specific health outcome associated with a given disease or injury, with further adjustment for co-morbidity and severity. A Bayesian meta-regression modelling tool, DisMod-MR (Disease Modelling-Meta Regression) 2.1, ensures consistency between all epidemiologic metrics for most causes [16]. HALE accounts for years of life spent in good health and serves as a summary for both mortality and morbidity [13]. It thus corresponds to specific LE by age and geography, adjusted for the years spent living with disability and disability weights. All estimates are reported with their 95% uncertainty intervals (UI). UIs are propagated throughout the estimating process where 1000 draws are generated for each point estimate, and the 95% UIs are obtained by selecting the 2.5th and 97.5th percentiles of the draws. This approach ensures robustness in identifying meaningful differences and trends in health outcomes over time.

Analytic strategies

The statistical significance of the difference between two estimates was defined as the absence of overlap between the 95% UI of those estimates. We analysed the overall (all ages and both sexes) and age group-specific rates for men and women. To analyse trends between 2010 and 2019, we relied on age-standardised rates and their relative changes since 2010. Difference between 2010 and 2019 was expressed in percentage change since 2010 (i.e. %*change*₂₀₁₀₋₂₀₁₉ = $\frac{estimate_{2019} - estimate_{2010}}{estimate_{2010}} \times 100$). In the GBD 2019 study, the same methodology is applied across years, including for 2010 and 2019. Age-standardisation is based on the GBD 2019 world standard population, which adjusts for differences in age distributions across populations, ensuring comparability between groups with different age structures. These rates were calculated using methodologies outlined in the GBD study, which provides upper and lower bounds of the estimates, allowing for a comprehensive analysis of trends over time.

The GBD arranges diseases and injuries (causes) into hierarchically nested categories in four levels of aggregation. At every level of aggregation, causes are mutually exclusive and collectively exhaustive. We extended this analysis focusing on each of the 22 Level 2 causes, and including seven Level 2 causes from Level 1 in the "communicable, maternal, neonatal and nutritional diseases" group (enteric infections, respiratory infections and tuberculosis, HIV/AIDs and sexually transmitted infections, maternal and neonatal disorders, neglected tropical diseases and malaria, nutritional deficiencies, other infectious diseases), 12 in the "non-communicable diseases" (NCDs) group (cardiovascular diseases, chronic respiratory diseases, diabetes and kidney diseases, digestive diseases, mental disorders, musculoskeletal disorders, neoplasm, neurological disorders, sense organ diseases, skin and subcutaneous diseases, substance use disorders, other NCDs), and three in the "injuries" group (self-harm and interpersonal, unintentional injuries and transport injuries). We considered Level 2 causes to focus the analysis on broad disease categories due to their policy implications. These causes represent broad disease categories where policy implications can result in benefits for all conditions summarized in these broader categories. We thus provide insights into the major drivers of health outcomes within the population.

All results are based on the estimates extracted from the Global Burden of Disease Results database and GBD Compare [20, 21]. All analyses were carried out with the open-source R Statistical Software (version 3.4, Foundation for Statistical Computing, Vienna, Austria) [22]. The GBD study adheres to the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) standards developed by WHO and others [23].

Results

Overall disease burden in the European Union

In 2019, the EU-27 had a total of 5,354,279 (95% UI: 5,206,626; 5,502,691) all-cause deaths, yielding a crude death rate of 1040.3 (95% UI: 1011.6; 1069.1) per 100 000 inhabitants. The age-standardised death rate for all causes was 465.8 (95% UI: 451.2; 480.9) per 100,000 inhabitants in the EU, with high variability across countries, ranging from 894.8 per 100,000 in Bulgaria to 385.9 per 100,000 in Spain. The total number of all-cause DALYs was 157,884,271 (95% UI: 139,041,970; 178,511,173), with a crude rate of 30,675 (95% UI: 27,014; 34,683) per 100,000 inhabitants. The all-cause age-standardised DALY rate per 100 000 inhabitants in 2019 was 20 251.0 (95% UI: 17 408.1; 23 513.9).

Eight countries (Bulgaria, Romania, Latvia, Hungary, Lithuania, Slovakia, Croatia, and Poland) reported significantly higher (i.e., the lower limit of the individual country 95% UI was higher than the upper limit of the EU 95% UI) all-cause age-standardised death rates than the EU. In contrast, nine countries (Spain, Italy, France, Luxembourg, Sweden, Malta, Austria, Finland, and Ireland) had significantly lower rates than the EU (Fig. 1A; Table 1). The all-cause age-standardised death rate in the EU declined on average by 8.8% (95% UI: -11.7; -5.9), ranging from -4.8% (95% UI: -7.2; -2.3) in Greece to -18.5% (95% UI; -30.7%; -4.5%) in Lithuania.

In 2019, compared to the EU, all-cause age-standardised DALY rates were significantly higher only in Bulgaria (Fig. 1B; Table 1). All-cause age-standardised DALY rates have declined significantly since 2010 (i.e., the upper limit of the 95% UI below zero) in most countries, except for Bulgaria, Croatia, Czechia, Estonia, Hungary, Romania, Slovakia, and Slovenia. Whilst most countries showed a decreasing trend in all-cause age-standardised YLL rates, no significant changes were found in all-cause age-standardised YLD rates between 2010 and 2019. Only Belgium, Lithuania, Portugal, and Slovenia experienced significant declines, while the Netherlands experienced significant increases in YLD rates (Table 1).

In 2019, life expectancy in the EU at birth was 81.0 years, ranging from 73.3 years in Bulgaria to 83.1 years in Italy and Spain. All countries experienced improvements in life expectancy between 2010 and 2019, with Lithuania having the highest increase (4.5%) and the EU-27 showing a 1.4% increase (from

79.8 years to 81.0 years). HALE at birth for the EU in 2019 was 69.8 years, ranging from 64.6 years in Bulgaria to 71.6 years in Spain, with HALE at birth improving by 1.2% between 2010 (i.e. 69.0 years) and 2019 across the EU-27. However, the gap between life expectancy and HALE widened from 10.8 years (13.6% of LE) in 2010 to 11.2 in 2019 (13.8% of LE), which suggests that YLDs represent a growing share of DALY rates.

Overall disease burden by age and sex

DALY rates increased similarly with age in both males and females. However, across the EU in 2019, for most age groups, DALY rates were higher among males than females (Fig. 2). For males, DALY rates were mostly driven by YLLs in those aged above 44 years of age and by YLDs among younger (<44 years old) age groups. For females, this cut-off occurred at a more advanced age, with DALY rates mostly driven by YLLs in groups aged above 64 years. YLLs dominated over YLDs in both sexes particularly in age extremes, i.e. younger and older age groups (Fig. 2).

Main causes of ill health

In 2019, the age-standardised death rates for cardiovascular diseases were significantly higher than the EU rate (159.0; 95% UI 142.2; 169.2) in most Central and Eastern European countries, with the highest values in Bulgaria, Romania, and Latvia, and significantly lower than the EU rate in some Western European countries (Fig. 1A). A similar geographic pattern was observed for age-standardised DALY rates for cardiovascular diseases, the second leading cause of age-standardised DALY in the EU (Fig. 1B).

Compared to the EU, the age-standardized death (143.6; 95% UI 133.8; 150.1) and DALY (3,342; 95% UI 3,175; 3,505) rates for neoplasms in 2019 were significantly lower in Spain, Sweden, Malta, Austria, and Finland (Fig. 1A and B). Hungary and Netherlands showed a significantly higher age-standardised death rate, with Hungary and Poland having a significantly higher age-standardized DALY rate (Fig. 1A and B). In fact, the age-standardised death rate in Hungary was almost two times higher than in France. Neoplasms were the leading cause of age-standardized DALY and the second highest cause of age-standardised mortality across the EU in 2019.

Digestive diseases are another example of high variability in death rates in EU countries. The highest (in Romania) to the lowest (in Malta) age-standardised death rates ratio is over 3.2. Additionally, countries of Central and Eastern Europe (Romania, Lithuania, Bulgaria, Hungary, Slovakia, Latvia, Poland) had significantly higher DALY rates than the EU rate.

rnal and neonatal	
ders	
culoskeletal	
ders	
ric infections	
and subcutaneous ases	
r infectious diseases	
AIDS and sexually	
tional deficiencies	
tal disorders	
ected tropical ases and malaria	

| A | All causes | Cardiovascular diseases | k Neoplasms | | _ | Digestive diseases | Chronic respiratory
diseases
 | Diabetes and kidney
diseases
 |
 | _ | Self-harm and interpersonal violence | Other non-communicable
diseases
 | Transport injuries
 | Substance use disorders | Maternal and neonatal
disorders | Musculoskeletal
disorders | Enteric infections | K Skin and subcutaneous diseases | | HIV/AIDS and sexually
transmitted infections | Nutritional deficiencies | Mental disorders
 | Neglected tropical
diseases and malaria |
|---|---|---|---|--|--|---
--
---|---

--|---|--
---|--
---|--|---|--|--|---|--|--
--|
| EU-27
Spain | 465.8
385.9 | 159.0
106.8 | 143. | | | 23.8
21.0 | 22.0
29.0
 | 19.0
19.2
 | 15.0
 | 13.1
8.9 | 10.2
6.4 | 9.1
 | 6.2
5.5
 | 4.8
1.8 | 3.3
2.7 | 1.4
1.2 | 1.1 | 1.0
1.3 | 1.0
0.9 | 0.6 | 0.6
0.4 | 0.02
 | 0.02 |
| Italy | 386.8 | 126.1 | 127. | | | 7.7 | 16.8
 | 20.9
 | 6.8
 | 9.4 | 5.7 | 7.2
 | 6.8
 | 1.0 | 2.7 | 1.2 | 0.6 | 0.7 | 0.9 | 0.8 | 0.4 | 0.01
 | 0.03 |
| France | 387.5 | 91.4 | 140. | | | 9.6 | 12.8
 | 14.2
 | 12.3
 | 19.2 | 13.3 | 9.1
 | 6.4
 | 5.6 | 3.4 | 1.9 | 0.9 | 1.3 | 1.1 | 0.6 | 2.2 | 0.03
 | 0.01 |
| Luxembourg | 389.2 | 116.0 | | | | 20.2 | 19.9
 | 16.3
 | 11.8
 | 13.7 | 9.7 | 6.2
 | 5.9
 | 5.2 | 2.0 | 0.9 | 1.5 | 0.7 | 1.7 | 0.4 | 0.6 | 0.03
 | 0.06 |
| Sweden | 397.9 | 138.6 | 120. | | | 4.2 | 17.8
 | 16.0
 | 10.9
 | 11.8 | 11.9 | 7.1
 | 3.4
 | 6.7 | 2.2 | 1.5 | 2.7 | 1.4 | 1.1 | 0.2 | 0.5 | 0.01
 | 0.01 |
| Malta | 400.4 | 146.7 | 108. | | | 3.4 | 15.4
 | 22.7
 | 18.9
 | 10.0 | 5.5 | 10.2
 | 4.7
 | 2.3 | 5.5 | 1.0 | 0.3 | 4.0 | 0.9 | 0.3 | 0.1 | 0.01
 | 0.18 |
| Austria
Finland | 420.8 | 150.6 | 122.
115. | | | 8.2
2.9 | 16.9
14.6
 | 26.2
8.7
 | 5.9
5.6
 | 12.5
15.3 | 12.0
14.4 | 11.2
5.9
 | 5.2
4.9
 | 5.0
11.6 | 2.7
1.6 | 1.1
1.4 | 0.6 | 0.4 | 0.8
0.8 | 0.3 | 0.1 | 0.05
 | 0.02 |
| Ireland | 430.5 | 173.8
132.8 | 137. | | | 5.6 | 32.4
 | 15.3
 | 22.2
 | 8.2 | 8.7 | 5.9
10.3
 | 3.4
 | 5.4 | 2.6 | 2.1 | 0.3 | 1.0 | 0.8 | 0.1 | 0.1 | 0.01
 | 0.00 |
| Portugal | 439.9 | 127.9 | | | | 21.9 | 23.7
 | 28.3
 | 28.5
 | 10.0 | 9.3 | 11.4
 | 7.7
 | 1.5 | 2.6 | 1.1 | 0.9 | 0.8 | 0.0 | 3.7 | 0.6 | 0.00
 | 0.00 |
| Netherlands | 443.1 | 113.0 | | | | 7.9 | 28.6
 | 18.9
 | 16.7
 | 13.1 | 9.9 | 11.8
 | 3.8
 | 2.6 | 3.6 | 1.9 | 1.1 | 2.0 | 1.3 | 0.2 | 0.5 | 0.04
 | 0.01 |
| Slovenia | 447.4 | 151.1 | 144. | 4 31 | .2 2 | 26.0 | 12.7
 | 12.3
 | 13.3
 | 17.9 | 14.5 | 5.8
 | 6.7
 | 7.2 | 1.8 | 1.2 | 0.1 | 0.3 | 0.6 | 0.1 | 0.0 | 0.00
 | 0.01 |
| Belgium | 449.5 | 118.6 | | _ | | 22.8 | 27.6
 | 16.3
 | 21.6
 | 17.1 | 16.3 | 10.4
 | 7.1
 | 4.6 | 2.9 | 1.4 | 3.0 | 1.8 | 1.5 | 0.4 | 1.2 | 0.02
 | 0.01 |
| Denmark | 462.4 | 118.8 | | | | 23.3 | 36.0
 | 20.6
 | 18.7
 | 10.8 | 9.2 | 10.3
 | 4.5
 | 11.8 | 3.6 | 2.4 | 2.9 | 0.9 | 1.1 | 0.4 | 0.6 | 0.01
 | 0.01 |
| Germany | 462.5 | 159.4 | 140. | | | 25.0 | 20.8
 | 24.8
 | 11.3
 | | 10.2 | 9.3
 | 4.7
 | 6.3 | 3.0 | 0.9 | 1.8 | 1.0 | 0.9 | 0.4 | 0.3 | 0.03
 | 0.01 |
| Greece
Cyprus | 472.9 | 186.8 | 143. | _ | | 21.8 | 20.4
 | 20.1
48.1
 | 19.4
11.8
 | 9.3
15.3 | 4.5
5.6 | 7.1
 | 11.1
14.4
 | 2.1
1.6 | 3.4
3.4 | 0.5 | 0.2 | 0.2 | 0.7 | 0.2 | 0.0 | 0.02
 | 0.07 |
| Czechia | 541.0 | 232.2 | 145. | | | 21.8 | 18.4
 | 21.5
 | 16.3
 | 16.1 | 11.5 | 6.4
 | 7.1
 | 3.9 | 2.5 | 0.6 | 1.4 | 0.6 | 0.7 | 0.3 | 0.5 | 0.00
 | 0.02 |
| Poland | 583.8 | 235.6 | | | | 28.0 | 15.4
 | 17.8
 | 17.8
 | 16.0 | 15.0 | 6.8
 | 9.5
 | 8.6 | 3.1 | 0.9 | 0.4 | 0.3 | 0.7 | 0.3 | 0.2 | 0.00
 | 0.01 |
| Estonia | 584.3 | 270.6 | | _ | _ | 25.0 | 10.3
 | 16.8
 | 10.5
 | _ | 15.9 | 6.3
 | 6.0
 | 22.1 | 1.7 | 1.1 | 0.1 | 0.7 | 0.9 | 2.6 | 0.1 | 0.00
 | 0.00 |
| Croatia | 591.3 | 265.8 | 159. | 8 31 | .7 2 | 26.4 | 19.5
 | 21.6
 | 7.1
 | 18.8 | 12.0 | 8.7
 | 8.4
 | 5.1 | 3.7 | 1.1 | 0.4 | 0.2 | 0.6 | 0.2 | 0.0 | 0.00
 | 0.01 |
| Slovakia | 623.9 | 298.9 | 152. | _ | _ | 34.6 | 12.6
 | 17.4
 | 22.1
 | 18.6 | 11.6 | 7.7
 | 8.0
 | 3.2 | 4.3 | 0.5 | 0.3 | 0.4 | 0.9 | 0.2 | 0.1 | 0.00
 | 0.01 |
| Lithuania | 666.1 | 328.8 | | _ | _ | 37.5 | 12.2
 | 8.7
 | 14.0
 | 28.2 | 28.4 | 8.1
 | 8.6
 | 14.3 | 2.3 | 1.0 | 0.3 | 0.9 | 1.2 | 1.9 | 0.1 | 0.00
 | 0.01 |
| Hungary | 667.5 | 301.6 | | | | 86.0 | 29.7
 | 21.3
 | 7.0
 | 16.9 | 14.8 | 8.8
 | 7.3
 | 4.1 | 3.5 | 1.3 | 1.4 | 0.6 | 0.8 | 0.4 | 0.2 | 0.00
 | 0.01 |
| Latvia | 685.3
716.5 | 356.8
379.6 | 143.
148. | _ | | 26.9
13.2 | 9.9
20.8
 | 14.5
14.3
 | 12.1
24.9
 | 26.3 | 21.7 | 9.8
6.5
 | 9.8
11.5
 | 13.1
2.5 | 3.1
5.4 | 1.0
0.3 | 0.1 | 1.3
0.3 | 1.4
1.1 | 5.6
0.8 | 0.2 | 0.00
 | 0.05 |
| Romania
Bulgaria | 894.8 | 541.1 | 161. | _ | | 35.3 | 20.8
 | 30.2
 | 17.7
 | 15.0 | 13.0 | 8.2
 | 9.8
 | 2.5 | 5.5 | 0.3 | 0.4 | 0.3 | 1.6 | 0.6 | 0.3 | 0.00
 | 0.03 |
| В | | | ar diseas | ıtal | ers | munica | -
 | orders
 | uries
 | | 2 | aneou
 | disorders
 | 000 | ence | natal | | ions | lcies | | seas | sexually
ections
 | l
aria |
| | All causes | Neoplasms | Cardiovascul | Musculoskele
disorders | Mental disorde | Other non-com | diseases
 | Neurological dis
 | Unintentional inj
Diabetes and kic
 | diseases | Chronic respirato | diseases
Skin and subcutaneous
 | e use
 | Self-harm and | Sense organ dise | Maternal and neo | Transport injuries | Respiratory infect
and tuberculosis | Nutritional deficier | Enteric infections | Other infectious di | HIV/AIDS and se
transmitted infect
 | Neglected tropical
diseases and mal- |
| EU-27 | All causes | Neoplasms | Cardiovascular diseases | Musculoskeletal | 84 Mental disorders | A Other non-communicable | 550 14
 | 108 11
 |
 | 97 76 | 5 75 | 4 diseases 8 Skin and
 | diseases
Substance use
 | 3 491 | | 452 | 427 | Bespiratory infections | 144 | D Enteric infections | G Other infectious diseases | HIV/AIDS and sexual transmitted infections
 | Neglected tropical diseases and malaria |
| Spain | ₹
20251
18033 | 3342
2977 | 2759
1834 | 2020
1831 | 187
219 | 4 15
2 14 | 550 14
472 13
 | 108 11
350 9
 | 118 7
10 7
 | 97 76
89 55 | 65 75
51 75 | 2 diseases
8 Skin and
8 Skin and
 | 0 0 0 0 0 0 0 0 0 0
 | 3 49 ⁻
9 309 | l 484
9 538 | 452
3380 | 427
349 | 369
281 | 144
125 | 100
84 | 56
54 | 9 h HIV/AIDS and transmitted infe
 | 12
20 |
| Spain
Italy | ₹
20251
18033
18186 | 3342
2977
2976 | 2759
1834
2032 | 2020
1831
2184 | 187
219
195 | 4 15
2 14
4 15 | 550 14
472 13
532 14
 | 408 11
350 9
472 7
 | 118 7
10 7
84 8
 | 97 76
89 55
14 64 | 5 75 51 75 14 53 | brian diseases
6 2 4 diseases
6 6 5
7 3
7 3
7 4 diseases
7 3
7 4 diseases
7 3
7 4 diseases
 | 300 100 300 100 300 100 300 100
 | 3 491 9 309 4 284 | 484 538 1 530 | 452
3380
413 | 427
349
422 | 369
281
225 | 144
125
145 | 100
84
59 | 56
54
47 | 9 4 HIV/AIDS and transmitted infe
 | 12
20
4 |
| Spain
Italy
France | ₹ 20251 18033 18186 18782 | 3342
2977
2976
3311 | 2759
1834
2032
1628 | 2020
1831
2184
2055 | 187
219
195
204 | 4 15
2 14
4 15
5 16 | 550 14
472 13
532 14
602 14
 | 408 11
350 9
472 7
426 12
 | 118 7
10 7
84 8
279 4
 | 97 76 89 55 14 64 63 56 | 5 75 51 75 4 53 55 55 | pue diseases
4 68
2 69
7 3
4 84
 | diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
diseases
dis
dis
diseases
dis
dis
dis
dis
dis
dis
dis
dis
dis
di
 | 3 49 ⁻ 9 309 4 28 ² 7 609 | 484 538 538 530 402 | 4 452
3 380
0 413
2 419 | 427
349
422
418 | 369
281
225
278 | 144
125
145
149 | 100
84
59
72 | 56
54
47
56 | HIV/AIDS and transmitted infi
 | 12
20
4
2 |
| Spain
Italy | ₹
20251
18033
18186 | 3342
2977
2976 | 2759
1834
2032 | 2020
1831
2184 | 187
219
195
204 | 4 15
2 14
4 15
5 16 | 550 14
472 13
532 14
502 14
496 13
 | 108 11 350 9 172 7 126 12 366 10
 | 118 7 10 7 84 8 279 4 091 8
 | 97 76
89 55
14 64 | 5 75 51 75 4 53 55 55 0 78 | seases
4 684
9 733
4 843
7 723
 | All Cliceases 0100 4 <td>3 49⁻¹ 9 309 4 28² 7 609 4 467</td> <td>484 538 538 538 402 402 380</td> <td>4 452
3 380
0 413
2 419
0 347</td> <td>427
349
422</td> <td>369
281
225
278
275</td> <td>144
125
145</td> <td>100
84
59</td> <td>56
54
47</td> <td>9 4 HIV/AIDS and transmitted infe</td> <td>12
20
4</td>
 | 3 49 ⁻¹ 9 309 4 28 ² 7 609 4 467 | 484 538 538 538 402 402 380 | 4 452
3 380
0 413
2 419
0 347 | 427
349
422 | 369
281
225
278
275 | 144
125
145 | 100
84
59 | 56
54
47 | 9 4 HIV/AIDS and transmitted infe
 | 12
20
4 |
| Spain
Italy
France
Luxembourg
Sweden
Malta | E 20251 18033 18186 18782 18634 18069 18983 | 3342 2977 2976 3311 2933 2672 2604 | 2759
1834
2032
1628
1981
2329
2511 | 2020
1831
2184
2055
2141
2036
2224 | 187 219 195 204 185 201 190 | 14 12 14 15 5 16 17 13 | 550 14 472 13 532 14 502 14 602 14 496 13 386 13 740 13
 | 108 11 350 9 172 7 126 12 366 10 321 10 329 10
 | 118 7 10 7 84 8 279 4 091 8 010 6 075 9
 | 97 76 89 55 14 64 63 56 04 61 15 46 19 42 | 55 75 51 75 54 53 55 55 10 78 56 78 29 67 | See 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
 | also also
 | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 | 484 538 538 402 402 380 340 402 | 4 452 3 380 413 413 419 347 311 670 | 427
349
422
418
389
241
316 | 369 281 225 278 275 265 394 | 144 125 145 149 117 123 111 | 100 84 59 72 108 110 58 | 56
54
47
56
71
46
55 | 92 HIV/AIDS and 18 AIV/AIDS and 18 AV 19 A | 12
20
4
2
4
3
13 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria | 20251 18033 18186 18782 18634 18069 18983 19104 | 3342 2977 2976 3311 2933 2672 2604 2820 | 2759
1834
2032
1628
1981
2329 | 2020
1831
2184
2055
2141
2036
2224
1971 | 187 219 195 204 185 201 190 190 | 4 15 2 14 4 15 5 16 60 14 7 13 13 17 95 15 | 550 14 472 13 532 14 502 14 502 14 496 13 386 13 740 13 932 13
 | 108 11 350 9 172 7 126 12 366 10 321 10 329 10 326 10
 | 118 7 10 7 84 8 279 4 091 8 010 6 075 9 083 7
 | 97 76 89 55 14 64 63 56 04 61 15 46 19 42 90 61 | 55 75 51 75 54 53 55 55 10 78 56 78 29 67 74 65 | Sessessip
4 684
2 699
9 73
4 844
7 720
6 692
4 744
1 71
 | Base of the second se | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 | 484 538 538 402 402 380
340 405 392 | 4 452 3 380 0 413 2 419 0 347 0 311 5 670 2 412 | 427
349
422
418
389
241
316
332 | 369 281 225 278 275 265 394 208 | 144 125 145 149 117 123 111 103 | 100 84 59 72 108 110 58 77 | 56
54
47
56
71
46
55
49 | HIV/AIDS and HIV/AIDS and B B B B B B B B B B B B B B B B B B B | 12
20
4
2
4
3
13
17 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland | ¥ 20251 18033 18186 18782 18634 18069 18983 19104 19569 | 3342
2977
2976
3311
2933
2672
2604
2820
2606 | 2759
1834
2032
1628
1981
2329
2511
2408
2864 | 2020
1831
2184
2055
2141
2036
2224
1971
2037 | 187 219 195 204 185 201 190 190 190 188 | 4 15 2 14 34 15 55 16 60 14 7 13 93 17 95 19 97 14 | 550 14 472 13 532 14 602 14 496 13 386 13 740 13 932 13 484 13
 | 408 11 350 9 472 7 426 12 366 10 321 10 322 10 326 10 329 10 326 10 396 13
 | 118 7 10 7 84 8 279 4 091 8 010 6 075 9 083 7 396 6
 | 97 76 89 55 14 64 63 56 04 61 15 46 19 42 90 61 85 78 | 65 75 51 75 54 53 55 55 10 78 66 78 29 67 74 65 38 61 | Sessease
4 68-
2 69
9 73
4 84
7 722
6 69
6 69
4 74
4 74
1 71
8 74
8 74
8 74
8 74
8 74
8 74
8 74
8 74
 | 4 603 4 603 4 603 4 603 4 603 4 603 4 603 3 344 3 366 3 344 3 366 3 344 3 366 3 344 3 366 3 <t< td=""><td>3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734</td><td>484 9 538 1 530 402 402 7 380 1 340 1 340 2 392 4 388</td><td>4 452 3 380 0 413 2 419 0 347 0 311 5 670 2 412 3 267</td><td>427
349
422
418
389
241
316
332
323</td><td>369 281 225 278 275 265 394 208 198</td><td>144 125 145 149 117 123 111 103 100</td><td>100 84 59 72 108 110 58 77 68</td><td>56
54
47
56
71
46
55
49
43</td><td>HIV/AIDS and HIV/AIDS and HIV/A</td><td>12
20
4
2
4
3
13
17
3</td></t<> | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 | 484 9 538 1 530 402 402 7
380 1 340 1 340 2 392 4 388 | 4 452 3 380 0 413 2 419 0 347 0 311 5 670 2 412 3 267 | 427
349
422
418
389
241
316
332
323 | 369 281 225 278 275 265 394 208 198 | 144 125 145 149 117 123 111 103 100 | 100 84 59 72 108 110 58 77 68 | 56
54
47
56
71
46
55
49
43 | HIV/AIDS and HIV/A | 12
20
4
2
4
3
13
17
3 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland | 20251 18033 18186 18782 18634 18069 18983 19104 19569 19401 | 3342 2977 2976 3311 2933 2672 2604 2820 2606 3049 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193 | 2020
1831
2184
2055
2141
2036
2224
1971
2037
2273 | 187 219 195 204 185 201 185 201 190 190 188 220 | 4 15 2 14 4 15 5 16 60 14 7 13 7 13 95 19 97 14 92 16 | 550 14 472 13 532 14 602 14 496 13 386 13 740 13 932 13 484 13 6666 14
 | 408 11 350 9 472 7 426 12 366 10 321 10 329 10 326 10 329 10 326 10 396 13 404 9
 | 118 7 10 7 84 8 279 4 091 8 010 6 075 9 083 7 396 6 336 6
 | 97 76 89 55 14 64 63 56 04 61 15 40 19 42 90 61 85 78 22 40 | 55 75 51 75 54 53 65 55 10 78 66 78 29 67 74 65 38 61 65 96 | Sesses pue us of the sesses of
 | 4 600 4 600 5 66 6 66 6 66 6 66 6 66 6 66 6 66 6 66 6 69 6 66 6 69 8 466 1 65 8 92 8 82 | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 474 | 484 538 538 4530 530 402 380
1 340 380 402 392 392 388 4397 | 4 452 3 380 4132 419 2 419 311 347 5 6700 2 412 3 2677 | 427
349
422
418
389
241
316
332
323
236 | 369 281 225 278 275 265 394 208 198 373 | 144 125 145 149 117 123 111 103 100 95 | 100 84 59 72 108 110 58 77 68 69 | 56
54
47
56
71
46
55
49
43
46 | HIV/AIDS and
B B C C C C C C C C C C C C C C C C C C | 12
20
4
2
4
3
13
13
17
3
2 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal | ₹ 20251 18033 18186 18782 18634 18069 18983 19104 19569 19401 19674 | 3342 2977 2976 3311 2933 2672 2604 2820 2606 3049 3135 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150 | 2020
1831
2184
2055
2141
2036
2224
1971
2037
2273
2256 | 187 219 195 204 185 201 190 190 190 190 201 201 201 190 190 201 | 4 15 2 14 4 15 5 16 0 14 7 13 03 17 95 19 97 14 92 16 7 12 93 17 | 550 14 472 13 532 14 602 14 496 13 386 13 740 13 932 13 484 13 666 14 4428 12
 | 408 11 350 9 472 7 426 12 366 10 321 10 322 10 326 10 326 10 326 10 329 10 326 10 329 10 329 10 329 10 329 10
 | 118 7 10 7 84 8 279 4 91 8 910 6 975 9 983 7 396 6 36 6 880 9
 | 97 76 89 55 14 64 63 56 04 67 115 46 119 42 90 67 885 78 222 46 880 62 | 55 755 51 755 44 533 55 555 10 788 209 677 74 655 388 611 555 966 224 866 | Sesses pue 4 684 2 699 9 73 4 844 7 728 6 692 4 744 7 744 7 744 8 744 9 728 1 71 8 744 9 728 1 73
 | esn estression
session and the session of the sessi | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 474 7 422 | 484 9 538 4 530 4 530
 9 402 7 380 1 340 2 392 388 397 41 397 2 413 | 4 452 3 380 413 413 2 419 311 347 3 347 3 347 3 347 3 347 3 347 3 347 3 347 3 360 3 374 | 427 349 422 418 389 241 316 332 323 236 422 | 369 281 225 278 275 265 394 208 198 373 527 | 144 125 145 149 117 123 111 103 100 95 136 | 100 84 59 72 108 110 58 77 68 | 56
54
47
56
71
46
55
49
43
46
54 | HIV/AIDS and
HIV/AIDS and
88
80
80
81
80
80
81
80
80
81
80
80
80
80
80
80
80
80
80
80
80
80
80 | 12
20
4
2
4
3
13
17
3
2
2
21 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland | 20251 18033 18186 18782 18634 18069 18983 19104 19569 19401 | 3342 2977 2976 3311 2933 2672 2604 2820 2606 3049 3135 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193 | 2020
1831
2184
2055
2141
2036
2224
1971
2037
2273
2256 | 187 219 195 204 185 204 185 201 185 201 190 190 190 190 190 190 201 203 204 205 | 4 15 2 14 4 15 5 16 0 14 7 13 03 17 95 19 97 14 92 16 7 14 93 16 | 550 14 472 13 532 14 602 14 496 13 386 13 740 13 932 13 484 13 5666 14 428 12 5663 14
 | 408 11 350 9 472 7 426 12 366 10 321 10 322 10 326 10 326 10 329 10 320 10 320 10 320 10 <td>118 7 10 7 84 8 279 4 91 8 010 6 075 9 083 7 396 6 36 6 80 9 74 6</td> <td>97 76 89 55 14 64 63 56 04 67 115 46 119 42 90 67 885 78 222 46 880 62</td> <td>55 75 51 75 54 53 55 55 10 78 66 78 29 67 74 655 88 61 824 86 838 97</td> <td>Seese Seese Seeses Seese Seese <t< td=""><td>83 83 84 600 84 600 83 466 83 344 83 566 83 669 83 666 83 666 83 666 83 662 83 663 84 652 83 662 83 662 84 652 84 623 84 633 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 <</td><td>3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 474 7 422
 8 480</td><td>484 538 538 4530 402 380 402 340 405 392 41 388 388 397 2 413 371</td><td>4 452 3 3800 4132 419 2 419 3311 311 5 6700 2 4123 3 2677 7 3603 3 3744 4 477</td><td>427 349 422 418 389 241 316 332 323 236 422 251</td><td>369 281 225 278 275 265 394 208 198 373 527 321</td><td>144 125 145 149 117 123 111 103 100 95</td><td>100 84 59 72 108 110 58 77 68 69 74</td><td>56
54
47
56
71
46
55
49
43
46</td><td>HIV/AIDS and
B B C C C C C C C C C C C C C C C C C C</td><td>12
20
4
2
4
3
13
13
17
3
2</td></t<></td> | 118 7 10 7 84 8 279 4 91 8 010 6 075 9 083 7 396 6 36 6 80 9 74 6
 | 97 76 89 55 14 64 63 56 04 67 115 46 119 42 90 67 885 78 222 46 880 62 | 55 75 51 75 54 53 55 55 10 78 66 78 29 67 74 655 88 61 824 86 838 97 | Seese Seeses Seese Seese <t< td=""><td>83 83 84 600 84 600 83 466 83 344 83 566 83 669 83 666 83 666 83 666 83 662 83 663 84 652 83 662 83 662 84 652 84 623 84 633 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 <</td><td>3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 474 7 422 8 480</td><td>484 538 538 4530 402 380 402 340 405 392 41 388 388 397 2 413 371</td><td>4 452 3 3800 4132 419 2 419 3311 311 5 6700 2 4123 3 2677 7 3603 3 3744 4 477</td><td>427 349 422 418 389 241 316 332 323 236 422 251</td><td>369 281 225 278 275 265 394 208 198 373 527 321</td><td>144 125 145 149 117 123 111 103 100 95</td><td>100 84 59 72 108 110 58 77 68 69 74</td><td>56
54
47
56
71
46
55
49
43
46</td><td>HIV/AIDS and
B B C C C C C C C C C C C C C C C C C C</td><td>12
20
4
2
4
3
13
13
17
3
2</td></t<>
 | 83 83 84 600 84 600 83 466 83 344 83 566 83 669 83 666 83 666 83 666 83 662 83 663 84 652 83 662 83 662 84 652 84 623 84 633 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 84 642 < | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 474 7 422 8 480 | 484 538 538 4530 402 380 402 340 405 392 41 388 388 397 2 413 371
 | 4 452 3 3800 4132 419 2 419 3311 311 5 6700 2 4123 3 2677 7 3603 3 3744 4 477 | 427 349 422 418 389 241 316 332 323 236 422 251 | 369 281 225 278 275 265 394 208 198 373 527 321 | 144 125 145 149 117 123 111 103 100 95 | 100 84 59 72 108 110 58 77 68 69 74 | 56
54
47
56
71
46
55
49
43
46 | HIV/AIDS and
B B C C C C C C C C C C C C C C C C C C | 12
20
4
2
4
3
13
13
17
3
2 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands | ₹ 20251 18033 18186 18782 18634 18069 18983 19104 19569 19401 19674 | 3342 2977 2976 3311 2933 2672 2604 2820 2604 3049 3135 3614 3341 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883 | 2020
1831
2184
2055
2141
2036
2224
1971
2037
2273
2256
2001 | 187 219 195 204 185 204 185 201 190 190 190 190 190 190 190 201 | 4 15 2 14 4 15 5 16 60 14 7 13 7 13 93 17 95 19 97 14 92 16 7 12 99 16 92 13 | 550 14 472 13 532 14 532 14 602 14 496 13 386 13 740 13 932 13 484 13 666 14 428 12 663 14 337 12
 | 408 11 350 9 472 7 426 12 366 10 321 10 3229 10 326 10 396 13 404 9 291 7 414 8 249 16
 | 118 7 10 7 84 8 279 4 911 8 010 6 075 9 083 7 396 6 36 6 374 6 594 6
 | 97 76 89 55 14 64 63 56 04 6 115 46 119 42 90 6 885 78 822 46 80 62 37 43 | 55 75 51 75 51 75 54 53 55 55 10 78 66 78 29 67 74 655 38 611 55 96 24 86 38 97 54 50 | Pure use See as a sec as a
 | esn
session and the session an | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 474 7 422 8 480 1 665 | 484 9 538 9 538 9 402 9 402 340 405 32 392 413 371 568
 | 4 452 3 380 0 413 2 419 347 347 0 311 5 6700 2 412 3 2677 3 3744 4777 360 3 366 | 427 349 422 418 389 241 316 323 226 422 418 389 241 316 323 226 422 251 635 | 369 281 225 278 275 265 394 208 198 373 527 321 277 | 144 125 145 149 117 123 111 103 100 95 136 109 127 | 100 84 59 72 108 110 58 77 68 69 74 | 56 54 47 56 71 46 55 49 43 46 54 54 55 60 | HIV/AIDS and
HIV/AIDS and
86
10
12
12
10
12
12
10
12
12
10
12
12
10
12
12
10
12
12
10
12
12
12
12
12
12
12
12
12
12
12
12
12 | 12
20
4
2
4
3
13
17
3
2
21
2 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia | ₹ 20251 18033 18186 18782 18634 18069 18983 19104 19569 19401 19674 18888 19135 | 3342 2977 2976 3311 2933 2672 2604 2820 2606 3049 3135 3614 3341 3256 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021 | 2020
1831
2184
2055
2141
2036
2224
1971
2037
2273
2256
2001
1521 | 187 219 195 204 195 204 185 201 190 190 190 190 190 190 190 190 190 190 190 188 201 2031 206 1466 187 | 4 155 12 14 44 155 15 166 17 133 17 133 17 14 15 19 16 19 17 14 18 19 19 16 12 16 12 16 12 16 12 16 13 17 14 19 16 10 | 550 14 472 13 532 14 502 14 602 14 496 13 386 13 740 13 932 13 484 13 5666 14 428 12 5663 14 337 12 788 15
 | 408 11 350 9 472 7 426 12 366 10 321 10 322 10 326 10 326 10 326 10 326 10 329 10 326 10 329 10 329 10 329 10 329 10 414 8 249 16 579 12
 | 118 7 10 7 84 8 279 4 911 8 910 6 975 9 983 7 396 6 360 9 774 6 3694 6 267 6
 | 97 76 89 55 14 64 63 56 04 6 15 46 19 42 90 6 885 78 22 46 80 62 37 43 97 88 | 55 755 51 755 54 53 55 55 10 78 66 78 29 67 74 65 38 611 65 96 24 86 38 97 64 50 11 87 | Session
4 68-
2 699
733
4 843
7 722
6 692
4 744
7 722
6 692
4 744
7 722
6 692
4 744
7 725
7 722
7 722
7 722
9 733
 | esine esine esine output output esine output esine esine <td>3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 472 7 422 8 480 1 6655</td> <td>484 9 538 4 530 402 7 380 4 402 392 403 388 392 41 388 397 2 413 397 2 413 397 2 413 397 5 568 9 409</td> <td>4 4522 3 380 413 380 2 419 3 347 3 311 5 670 2 412 3 2677 7 360 3 3744 4777 366 9 415</td> <td>427 349 422 418 389 241 316 332 2236 422 418 349 241 316 332 2236 422 251 635 440</td> <td>369 281 225 278 275 265 394 208 198 373 527 321 277 404</td> <td>144 125 145 149 117 123 111 103 100 95 136 109 127</td> <td>100 84 59 72 108 110 58 77 68 69 74 143</td> <td>56
54
47
56
71
46
55
49
43
46
54
60
42</td> <td>HIV/AIDS and
HIV/AIDS and
B
44
51
40
51
40
51
51
51
51
51
51
51
51
51
51
51
51
51</td> <td>12
20
4
2
3
13
13
17
3
2
21
2
8</td>
 | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 472 7 422 8 480 1 6655 | 484 9 538 4 530 402 7 380 4 402 392 403 388 392 41 388 397 2 413 397 2 413 397 2 413 397 5 568 9 409 | 4 4522 3 380 413 380 2 419 3 347 3 311 5 670 2 412 3 2677 7 360 3 3744 4777 366 9 415 | 427 349 422 418 389 241 316 332 2236 422 418 349 241 316 332 2236 422 251 635 440 | 369 281 225 278 275 265 394 208 198 373 527 321 277 404 | 144 125 145 149 117 123 111 103 100 95 136 109 127 | 100 84 59 72 108 110 58 77 68 69 74 143 | 56
54
47
56
71
46
55
49
43
46
54
60
42 | HIV/AIDS and
HIV/AIDS and
B
44
51
40
51
40
51
51
51
51
51
51
51
51
51
51
51
51
51
 | 12
20
4
2
3
13
13
17
3
2
21
2
8 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany | ₹ 20251 18033 18186 18782 18634 18069 18983 19104 19569 19674 18888 19135 20170 19929 20075 | 3342 2977 2976 3311 2933 2672 2604 2820 2606 3049 3135 3614 3341 3256 3494 3221 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021
1968
2601 | 2020
1831
2184
205552
2141
2036
2224
1971
2037
2256
2001
1521
2042
248552
2211 | 187 219 1955 204 1855 204 1855 201 190 190 190 190 190 190 190 201 190 201 190 201 201 188 201 189 | 4 155 144 155 155 160 177 133 177 133 177 144 12 160 12 160 12 160 12 160 12 160 12 160 12 160 12 160 13 177 14 177 14 177 14 177 | 550 14 472 13 532 14 602 14 496 13 5386 13 740 13 932 13 484 13 666 14 428 12 663 14 788 15 709 12 592 15
 | 408 11 350 9 426 12 366 10 321 10 322 10 323 10 324 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 320 10 320 10 320 11 320 12 320 12 320 12 320 12 320 12
 | 118 7 10 7 84 8 279 4 091 8 010 6 075 9 083 7 386 6 386 9 74 6 6394 6 267 6 267 6 267 6 267 6 267 6 267 6 267 6 267 6 267 6 267 6 267 6 267 6
 | 97 76 89 55 14 64 63 56 004 61 115 46 119 42 900 62 885 78 22 46 80 62 37 43 997 86 994 64 78 68 94 74 | 55 755 51 755 44 53 55 55 10 78 66 78 29 67 74 655 88 61 55 96 24 86 88 97 64 50 11 87 36 103 42 74 | sessessip
4 684
2 699
9 733
4 844
7 726
6 692
4 744
7 726
6 692
4 744
7 726
7 726
9 726
9 726
9 726
9 726
9 726
9 726
9 726
9 726
9 730
9 726
9 730
9 730
740
9 730
740
740
740
740
740
740
740
740
740
74
 | 937 938 941 600 942 94 943 46 944 600 945 94
 | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 5 734 4 474 7 422 8 480 1 6655 11 7699 0 423 8 477 | 484 538 4538 4538 402 7 380 402 392 4392 392 4397 2 397 397 397 397 397 397 397 397 397 393 374 | 4 4522 3 380 4132 419 2 419 3 347 3 311 5 6700 2 4123 3 2677 3 366 3 3741 4 4773 3 3666 3 4459 4 4593 4 4259 | 427 349 422 418 389 241 316 323 226 422 251 635 440 289 315 | 369 281 225 278 225 275 265 394 208 198 373 527 321 277 404 347 287 | 144 125 145 145 145 145 145 145 145 145 145 145 145 117 123 100 95 136 109 127 126 109 122 | 100 84 59 72 108 110 58 77 68 69 74 143 127 109 | 56 54 47 56 71 46 55 49 43 46 54 60 42 69 53 45 | 44 66 51 40 28 28 28 33 10 28 33 10 17 199 24 14 35 28 28 29
 | 12
20
4
3
13
17
3
2
21
2
2
8
2
3
3
3 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece | ₹ 20251 18033 18186 18722 18634 18069 18983 19104 19569 19401 19674 18888 19135 20170 19929 20075 20201 | 3342 2977 2976 3311 2933 2672 2604 2820 3049 3135 3614 3341 3256 3494 3221 3300 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021
1968
2601
3198 | 20202
1831
2184
2055
21411
2036
2224
1971
2037
2256
20011
521
2042
2485
22111
2032
2211
2031 | 187 219 195 201 195 204 185 2011 185 2011 190 190 190 190 190 201 190 201 190 201 201 201 201 201 201 201 201 201 201 201 201 201 201 201 201 201 201 202 203 146 189 204 205 | 4 155 144 155 144 155 145 160 147 133 157 143 155 199 162 162 163 177 142 162 155 199 162 135 155 177 144 177 158 160 155 175 | 550 14 472 13 532 14 602 14 602 14 496 13 3386 13 740 13 932 13 484 13 666 14 428 12 663 14 337 12 788 15 709 12 592 15 591 13
 | 408 11 350 9 426 12 366 10 321 10 322 10 324 10 325 10 326 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 329 10 320 12 320 9 330 9
 | 118 7 10 7 84 8 279 4 91 8 91 8 91 8 91 6 975 9 983 7 396 6 366 6 80 9 74 6 694 6 267 6 267 6 267 6 267 8 407 7
 | 97 76 89 55 14 64 63 50 004 61 115 46 190 61 192 42 900 62 327 43 997 88 994 64 778 68 994 74 994 74 994 74 994 74 994 74 990 41 | 55 755 51 755 51 755 54 53 55 55 10 78 66 78 29 67 74 65 88 61 55 96 24 86 88 97 64 50 11 87 36 103 42 74 70 72 | Sessessip Pure Pure 4 68- 69- 9 73: 4 4 84: 7 7 726 6 9 73: 1 7 726 726 1 711 73: 7 725 455 9 73: 770 9 73: 770 9 73: 770 9 73: 770 9 73: 770 9 73: 770 9 71: 74: 9 73: 770 9 71: 74: 9 71: 74:
 | 97 97 98 97 98 97 98 97 98 97 98 97 98 97
 | 3 491 9 309 4 284 7 609 4 467 2 591 6 311 9 552 734 474 7 422 8 480 1 665 1 769 0 423 8 477 2 242 | 4844 538 4538 538 4538 402 7 380 402 392 413 397 413 397 413 397 413 397 413 397 413 397 413 397 413 397 413 397 413 397 413 397 413 397 413 397 393 372 415 | 4 4522 3 380 4132 419 2 419 3 347 3 311 5 6700 2 4123 3 2677 3 366 9 415 4 459 3 442 9 476 | 427 349 422 418 389 241 316 323 226 422 251 635 440 289 315 672 | 369 281 225 278 275 265 394 208 198 373 527 321 277 404 347 287 408 | 144 125 145 145 145 145 145 145 145 145 145 145 145 145 145 145 117 123 100 95 136 109 127 126 109 122 83 | 100 84 59 72 108 110 58 77 68 69 74 143 131 127 109 69 | 56 54 47 56 71 46 55 49 43 46 54 60 42 69 53 45 | pus SULVIH 44
66
51
40
28
8
8
8
6
33
10
17
199
24
14
35
28
29
18
 | 12
20
4
3
13
17
3
2
2
2
2
2
8
2
3
3
3
19 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus | ₹ 20251 18033 18186 18782 18634 18983 19104 19569 19401 19674 18888 19135 20170 19929 20075 20201 19743 | 3342 2977 2976 3311 2933 2672 2604 2820 3049 3135 3614 3341 3256 3494 3221 3300 2648 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021
1968
2601
3198
2939 | 20202
1831
2184
2055
2141
2036
2224
1971
2037
2256
2001
1521
2042
2485
22111
2042
2485
2211
2042
2255
2011
2042
2255
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015 | 187 219 195 201 195 204 185 2011 185 2011 190 190 190 190 190 190 190 190 190 190 190 190 190 190 188 206 1466 187 189 2266 191 | 4 155 12 144 15 160 14 155 160 147 133 177 143 155 15 199 12 160 12 160 12 160 12 160 12 160 12 160 12 160 13 177 14 177 14 177 14 177 14 177 14 177 14 177 14 177 15 15 15 15 | 550 14 472 13 532 14 602 14 496 13 386 13 740 13 932 13 484 13 666 14 428 12 663 14 788 15 709 12 592 15 591 13
 | 11 350 9 172 7 126 12 366 10 321 10 3229 10 326 10 329 10 326 10 329 10 326 10 329 10 329 10 320 10 329 10 320 10 321 10 322 10 323 10 3330 10
 | 118 7 10 7 84 8 279 4 91 8 9291 8 910 6 975 9 983 7 396 6 366 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 6 364 7 364 7 364 7 364 1
 | 97 76 89 55 14 64 63 56 04 6 15 40 19 42 90 6 85 74 80 62 37 43 97 86 94 64 97 86 94 64 95 74 96 44 97 86 94 64 95 74 96 44 97 86 94 74 90 43 165 44 | 55 755 51 755 51 755 54 53 55 555 10 78 56 78 59 67 74 655 55 96 24 86 38 61 55 96 24 86 38 97 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 54 50 55 56 56 | Signed Field Signed Field
 | 97 97 98 97 98 97 98 97 98 97 98 97 98 97 97 97 98 97 | 3 491 9 309 4 284 7 609 4 467 2 591 6
 311 9 552 734 474 7 422 8 480 1 665 1 769 0 423 8 477 2 242 8 311 | 4844 538 538 402 380 402 380 402 392 413 402 392 413 386 402 392 413 371 566 409 374 393 374 393 419 393 419 397 393 419 397 | 4 4522 3 3800 4132 4190 2 419 3311 5 5 6700 2 412 3 267 3 366 9 4159 3 442 4429 4766 7 457 | 427
349
422
418
389
241
316
332
323
236
422
251
635
440
289
315
672
773 | 369 281 225 278 275 265 394 208 198 373 527 321 277 404 347 287 408 264 | 144 125 145 145 145 145 145 145 145 145 145 145 145 145 145 145 117 123 111 103 100 95 136 109 127 126 109 122 83 112 | 100 84 59 72 108 110 58 77 68 69 74 143 131 127 109 69 99 | 56 54 47 56 71 46 55 49 43 46 54 60 42 69 53 45 38 | pus SUPAN 44
44
46
51
40
28
10
17
199
24
14
35
28
29
18
22
 | 12
20
4
3
13
17
3
2
2
2
2
2
8
2
3
3
3
19
3
3 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia | ₹ 20251 18033 18186 18782 18634 18069 18983 19104 19569 19401 19674 18888 19135 20170 19929 20075 202011 19743 21153 | 3342 2977 2976 3311 2933 2602 2604 2820 2606 3049 3135 3641 3256 3494 3221 3300 2648 3405 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021
1968
2021
1968
2021
3198
2939
3909 | 2020
1831
2184
205552
2141
2036
2224
1971
2037
2273
2256
2001
1521
1521
2042
248552
2211
2031
2225
1548 | 1877 219 1955 204 1855 201 1955 204 1855 201 190 190 190 190 190 190 201 202 188 206 1466 1877 189 2266 191 138 | 4 155 2 144 15 160 17 133 17 133 17 14 15 160 14 155 17 133 17 14 12 16 12 16 12 16 12 16 12 16 13 17 14 17 14 17 14 15 15 15 15 15 15 15 | 550 14 472 13 532 14 602 14 496 13 386 13 740 13 386 13 740 13 386 13 484 13 666 14 337 12 788 15 709 12 592 15 591 13 556 13 2271 12
 | 111 111 111
 | 118 7 10 7 84 8 279 4 911 8 901 8 910 6 975 9 983 7 396 6 396 6 396 6 394 6 394 6 394 6 394 6 267 6 267 6 267 6 267 6 267 6 267 6 260 6 70 8 447 7 2064 11 2661 12
 | 97 76 89 55 14 64 63 56 04 6 15 40 19 42 90 6 85 78 22 40 80 62 37 43 97 86 94 64 97 86 94 64 95 74 90 43 464 74 90 43 91 64 92 44 93 74 94 64 95 74 96 43 97 86 94 74 95 43 465 44 251 88 | 55 755 51 755 51 755 54 53 55 55 10 78 56 78 59 67 74 65 38 61 55 96 24 86 38 97 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 54 500 55 56 56 56 | 88 pue pue 99 pue pue 4 684 4 2 699 733 4 844 7 7 722 6 6 692 741 1 711 733 7 722 5 45 9 733 300 777 9 9 711 4 4 711 4 4 711 4
 | 91 92 92 93 92 92 93 46 93 46 93 46 93 346 94 900 95 97 96 89 97 611 97 4335 97 9356 91 91
 | 3 491 9 309 9 309 4 284 7 609 4 463 2 591 6 311 9 552 5 734 4 474 7 422 8 480 1 66551 11 7690 2 242 8 311 5 577 | 484 484 3 538 533 4 533 402 3 407 388 340 4 344 344 344 4 322 344 342 4 392 413 388 5 565 565 374 3 374 393 374 4 393 374 393 2 4193 397 393 2 4193 397 599 | 4 4522 3 3800 4132 4190 2 419 3311 5 5 6700 2 412 3 367 7 3600 3 3744 4777 3600 3 3744 4593 3666 9 4159 3 4429 9 4766 7 457 | 4277349
3499349
442241
3899241
316
332236
323323
236
635
6420
2899
315
6722
7773
656 | 369 281 225 278 275 265 394 208 198 373 5277 321 2777 404 347 287 408 287 408 395 | 144 125 145 149 117 123 111 103 95 136 109 127 126 109 122 83 112 144 | 100 84 59 72 108 110 58 77 68 69 74 143 131 127 109 69 99 189 | 56 54 47 56 71 46 55 49 43 46 54 60 42 69 53 45 38 49 | pue SGIV/NIH 44
66
51
40
28
26
33
10
17
17
24
14
35
28
29
18
22
29
18
22
21
7
 | 12
20
4
2
4
3
13
17
2
2
2
2
2
2
2
2
2
2
3
3
3
19
3
8
8 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia
Poland | ₹ 20251 18033 18186 18782 18634 18083 19104 19569 19401 19674 18888 19132 20170 19929 20075 20201 19743 21153 22749 | 3342 2977 2976 3311 2933 2672 2604 2820 2606 3049 3135 3644 3256 3494 3221 3300 2648 3405 4192 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2150
1883
2021
1968
2021
3198
2939
3909
4183 | 2020
1831
2184
20555
2141
2036
2224
1971
2037
2273
2256
2001
1521
2042
24855
22111521
2031
2225
1548
1628 | 1877 219 1955 204 1857 204 1855 2019 1955 204 1855 2019 190 190 190 201 201 201 201 201 201 201 201 201 201 202 202 203 1460 1489 2026 1911 1899 2266 1911 1388 1255 | 4 155 14 155 14 155 16 17 13 177 12 16 15 199 16 177 14 155 177 122 16 12 177 14 177 14 177 14 177 14 16 15 175 12 18 16 10 15 15 15 15 15 15 15 15 12 15 12 16 15 17 14 | 1472 1332 1472 1332 1472 1332 1472 1332 1472 1332 1472 1332 1496 13332 143333 13333 1444 13333 1556 14428 12428 12428 125551 13337 1217 12216
 | 111 111 1172 7 1172 7 1172 7 1172 7 1172 7 1172 7 1172 12 111 102 111 8 111 </td <td>118 7 10 7 84 8 8279 4 991 8 910 6 975 9 983 7 9966 6 9974 6 6394 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6394 7 7064 11 6267 9</td> <td>97 76 889 55 14 64 63 56 04 61 15 44 90 67 885 78 22 44 80 62 37 43 97 86 94 64 78 66 74 90 94 64 78 66 94 64 78 62 90 47 900 47 900 42 8251 83 551 10</td> <td>55 75 51 75 51 75 51 75 51 75 52 75 55 55 66 78 66 78 66 78 66 78 66 78 674 655 38 611 55 96 24 86 38 97 54 50 11 87 36 103 42 74 70 72 33 86 96 623 96 623</td> <td>88 pue pue</td> <td>93 90 92 90 93
 90 94 90 95 90 96 90 97 91 96 92 97 93 96 92 97 93 97 93 97 93 97 93 97 93 97 93 97 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 <</td> <td>3 499 3090 309 3090 3090 304 2844 2844 44 4665 31112 50 31112 31512 31 31512 31112 31 31512 31112 31 3112 31112 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3111 31111 31 3111 31111 31 31111 31111 31 31111 31111 31 31111 31111 31 31111 31111 31 31111 31111 31 31111 311111 31 311111 3111111</td> <td>484 484 3 538 539 4 533 402 3 402 344 4 344 349 4 402 344 4 402 344 4 344 344 4 344 344 4 344 344 4 344 344 5 5656 566 5 364 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 38 344 344 394 344 344 394 344 344 394 344 344 394 344<!--</td--><td>4 4522 3 380 0 4132 2 4190 3 347 0 311 5 6700 2 4123 3 2677 3 3669 4153 4679 4 4599 3 4422 9 4766 7 4377</td><td>42773349
4224113389
2411332233232323232323232323232323232323</td><td>3699 3699 28111 225 2752 2752 2654 2752 3944 3073 3211 3733 3212 3733 3213 3212 3214 4044 3477 2877 3404 3477 3405 3405 3406 3405 3407 3478</td><td>1444
125
145
149
117
123
149
117
123
149
117
123
100
95
136
100
95
136
100
95
136
100
95
127
126
109
95
122
122
126
145
149
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
117
123
149
117
117
123
149
117
117
123
149
117
117
117
117
117
117
117
117
117
11</td><td>100 84 59 72 108 110 58 76 68 74 74 143 131 127 109 99 189 121</td><td>56 54 47 56 71 46 55 49 46 54 60 42 69 53 45 38 49 55</td><td>pup SUP 24
4
6
6
5
1
4
0
28
26
33
10
17
17
24
14
35
28
29
18
22
17
27</td><td>12 20 4 2 4 3 13 17 3 2 21 2 8 2 3 19 3 8 42</td></td> | 118 7 10 7 84 8 8279 4 991 8 910 6 975 9 983 7 9966 6 9974 6 6394 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6267 6 6394 7 7064 11 6267 9
 | 97 76 889 55 14 64 63 56 04 61 15 44 90 67 885 78 22 44 80 62 37 43 97 86 94 64 78 66 74 90 94 64 78 66 94 64 78 62 90 47 900 47 900 42 8251 83 551 10 | 55 75 51 75 51 75 51 75 51 75 52 75 55 55 66 78 66 78 66 78 66 78 66 78 674 655 38 611 55 96 24 86 38 97 54 50 11 87 36 103 42 74 70 72 33 86 96 623 96 623 | 88 pue
 | 93 90 92 90 93 90 94 90 95 90 96 90 97 91 96 92 97 93 96 92 97 93 97 93 97 93 97 93 97 93 97 93 97 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 93 < | 3 499 3090 309 3090 3090 304 2844 2844 44 4665 31112 50 31112 31512 31 31512 31112 31 31512 31112 31 3112 31112 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3112 31111 31 3111 31111 31 3111 31111 31 31111 31111 31 31111 31111 31 31111 31111 31 31111 31111 31 31111 31111 31 31111 311111 31 311111 3111111 | 484 484 3 538 539 4 533 402 3 402 344 4 344 349 4 402 344 4 402 344 4 344 344 4 344 344 4 344 344
4 344 344 5 5656 566 5 364 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 37 344 344 38 344 344 394 344 344 394 344 344 394 344 344 394 344 </td <td>4 4522 3 380 0 4132 2 4190 3 347 0 311 5 6700 2 4123 3 2677 3 3669 4153 4679 4 4599 3 4422 9 4766 7 4377</td> <td>42773349
4224113389
2411332233232323232323232323232323232323</td> <td>3699 3699 28111 225 2752 2752 2654 2752 3944 3073 3211 3733 3212 3733 3213 3212 3214 4044 3477 2877 3404 3477 3405 3405 3406 3405 3407 3478</td> <td>1444
125
145
149
117
123
149
117
123
149
117
123
100
95
136
100
95
136
100
95
136
100
95
127
126
109
95
122
122
126
145
149
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
117
123
149
117
117
123
149
117
117
123
149
117
117
117
117
117
117
117
117
117
11</td> <td>100 84 59 72 108 110 58 76 68 74 74 143 131 127 109 99 189 121</td> <td>56 54 47 56 71 46 55 49 46 54 60 42 69 53 45 38 49 55</td> <td>pup SUP 24
4
6
6
5
1
4
0
28
26
33
10
17
17
24
14
35
28
29
18
22
17
27</td> <td>12 20 4 2 4 3 13 17 3 2 21 2 8 2 3 19 3 8 42</td> | 4 4522 3 380 0 4132 2 4190 3 347 0 311 5 6700 2 4123 3 2677 3 3669 4153 4679 4 4599 3 4422 9 4766 7 4377 | 42773349
4224113389
2411332233232323232323232323232323232323 | 3699 3699 28111 225 2752 2752 2654 2752 3944 3073 3211 3733 3212 3733 3213 3212 3214 4044 3477 2877 3404 3477 3405 3405 3406 3405 3407 3478 | 1444
125
145
149
117
123
149
117
123
149
117
123
100
95
136
100
95
136
100
95
136
100
95
127
126
109
95
122
122
126
145
149
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
149
117
117
123
149
117
117
123
149
117
117
123
149
117
117
117
117
117
117
117
117
117
11 | 100 84 59 72 108 110 58 76 68 74 74 143 131 127 109 99 189 121 | 56 54 47 56 71 46 55 49 46 54 60 42 69 53 45 38 49 55 | pup SUP 24
4
6
6
5
1
4
0
28
26
33
10
17
17
24
14
35
28
29
18
22
17
27 | 12 20 4 2 4 3 13 17 3 2 21 2 8 2 3 19 3 8 42 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia
Poland
Estonia | ₹ 20251 18033 18186 18782 18634 18063 19104 19569 19401 19674 18888 19135 20170 19929 20075 20201 19743 21153 22749 23061 | 3342 2977 2976 3311 2933 2672 2604 2820 2604 3049 3135 3614 3341 3256 3494 3221 3300 2648 3405 4192 3522 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021
3198
2021
3198
2939
3909
4183
4651 | 20202
18311
21844
205552
21411
2036
22244
1971
2037
2273
22566
2001
1521
2042
22485
22111
2032
22485
22111
2031
2225
1521
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015
2015 | 1877 219 1955 204 1855 201 1855 201 1855 201 1855 201 190 190 190 190 190 201 188 206 146 187 189 2266 1911 188 1255 157 | 4 155 14 155 16 16 17 133 17 133 17 14 15 16 16 12 17 14 17 14 17 14 17 14 17 14 17 14 16 17 14 17 14 17 14 17 14 17 14 17 14 17 15 15 15 15 15 15 15 15 16 14 17 14 16 15 15 15 12 13 | 14472 13332 14472 13332 14472 13332 14472 1401 13332 1441 1332 1441 1502 1444 1332 13332 1444 13332 1444 133333 1428 1433337 1428 14355 14355 14355
 | 111 3 112 7 112 12 112 12 112 12 112 12 112 12 112 12 112 12 112 12 112 12 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 114 8 115 9 116 9 117 12 118 12 119 12 110 </td <td>118 7 110 7 884 8 279 4 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9083 7 9083 7 90844 7 90844 7 90844 7 90845 7</td> <td>997 7(7) 889 5:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3</td> <td>55 755/1 75 75 75 75 75 75 75 75 75 75 76 78 77 75</td> <td>80 pure uses 90 pure uses 91 733 4 689 9 9 733 722 6 699 734 744 71 722 5 455 9 73300 77 722 9 7300 77 722 5 455 9 7300 77 722 9 7300 77 722 5 455 4 640 4 641 5 455</td> <td>93 93 92 93 93 93 93 93 94 94 95 97 93 34 94 90 95 97 91 45 92 99 93 46 93 36 94 600 95 35 96 355 94 511 95 355 96 355
97 611 97 612 97 613 96 355 97 614 97 763 96 355 97 614 97 763 97 763 97 763 97 763 97 764 97 764 97 764 <</td> <td>3 499 305 309 309 309 309 3044 288 428 288 4 465 311 49 55 7344 474 474 55 7344 474 474 405 55 7344 474 41 665 673 666 311 665 677 42 242 486 411</td> <td>4844 4845 3 5383 4 5334 5383 402 3846 402 3846 402 3942 3942 41313 377 3846 377 3934 377 3932 41313 377 3932 377 3923 3977 3923 3933 6324</td> <td>4 45254 4522 3800 41333 3800 41332 4199 4199 41333 5 6707 6707 360 3 3741 4199 4777 4199 4767 4190 3741 410 4599 47459 434459 477 43777 43177 431777 431777 431777</td> <td>42773349
4224113389
24113389
24113336
236
236
236
236
236
236
236
236
236</td> <td>3699 3699 2811 2255 278 2782 2765 265 3944 198 3733 3211 37777 2877 4044 3477 4044 3477 4034 39552 4084 4478</td> <td>1444
125
145
145
145
149
117
123
123
123
123
111
100
95
136
109
95
136
109
95
136
109
95
136
109
95
1227
126
130
127
127
126
145
145
145
145
145
145
145
145
145
145</td> <td>100 84 59 72 108 110 58 69 74 143 131 127 109 69 99 189 121 186</td> <td>56 54 47 56 71 46 55 49 46 54 60 42 69 53 45 38 49 55 62</td> <td>HIV/VIDS and transmitted intermediate of the second second</td> <td>12 20 4 2 3 13 17 3 2 21 2 3 42 31</td> | 118 7 110 7 884 8 279 4 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9091 8 9083 7 9083 7 90844 7 90844 7 90844 7 90845 7
 | 997 7(7) 889 5:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3:3 | 55 755/1 75 75 75 75 75 75 75 75 75 75 76 78 77 75 | 80 pure uses 90 pure uses 91 733 4 689 9 9 733 722 6 699 734 744 71 722 5 455 9 73300 77 722 9 7300 77 722 5 455 9 7300 77 722 9 7300 77 722 5 455 4 640 4 641 5 455
 | 93 93 92 93 93 93 93 93 94 94 95 97 93 34 94 90 95 97 91 45 92 99 93 46 93 36 94 600 95 35 96 355 94 511 95 355 96 355 97 611 97 612 97 613 96 355 97 614 97 763 96 355 97 614 97 763 97 763 97 763 97 763 97 764 97 764 97 764 < | 3 499 305 309 309 309 309 3044 288 428 288 4 465 311 49 55 7344 474 474 55 7344 474 474 405 55 7344 474 41 665 673 666 311 665 677 42 242 486 411 | 4844 4845 3 5383 4 5334
 5383 402 3846 402 3846 402 3942 3942 41313 377 3846 377 3934 377 3932 41313 377 3932 377 3923 3977 3923 3933 6324 | 4 45254 4522 3800 41333 3800 41332 4199 4199 41333 5 6707 6707 360 3 3741 4199 4777 4199 4767 4190 3741 410 4599 47459 434459 477 43777 43177 431777 431777 431777 | 42773349
4224113389
24113389
24113336
236
236
236
236
236
236
236
236
236 | 3699 3699 2811 2255 278 2782 2765 265 3944 198 3733 3211 37777 2877 4044 3477 4044 3477 4034 39552 4084 4478 | 1444
125
145
145
145
149
117
123
123
123
123
111
100
95
136
109
95
136
109
95
136
109
95
136
109
95
1227
126
130
127
127
126
145
145
145
145
145
145
145
145
145
145 | 100 84 59 72 108 110 58 69 74 143 131 127 109 69 99 189 121 186 | 56 54 47 56 71 46 55 49 46 54 60 42 69 53 45 38 49 55 62 | HIV/VIDS and transmitted intermediate of the second | 12 20 4 2 3 13 17 3 2 21 2 3 42 31 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia
Poland
Estonia
Croatia | ₹ 20251 18033 18186 18782 18634 18983 19104 19569 19674 18888 19135 20170 19920 20075 20201 19743 21753 23061 21886 | 3342 2977 2976 3311 2933 2672 2604 2820 2606 3049 3135 3644 3256 3494 3221 3300 2648 3405 4192 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2150
1883
2021
1968
2021
3198
2939
3909
4183 | 2020
1831
2184
20555
2141
2036
2224
1971
2037
2273
2256
2001
1521
2042
24855
22111521
2031
2225
1548
1628 | 1877 219 1955 219 1955 219 1955 201 1955 201 1955 201 190 190 190 190 190 201 188 206 146 187 188 206 191 188 206 191 188 206 191 188 206 191 188 1255 1577 1455 | 4 155 144 155 144 155 145 160 147 133 177 133 177 141 177 142 149 167 141 177 142 166 155 157 144 177 155 152 155 152 155 152 155 122 160 155 155 122 163 100 | 14472 13332 1472 1332 14472 13332 14 1472 13332 14 13 12 1496 13 13 13 13 13 1502 1444 13 13 13 13 13 13 13 13 13 13 14 13 13 14 13 13 14 13 13 14 13 13 14 13 13 14 13 13 14 13 14 13 14 13 14 13 14 13 14 13 14 13 14 13 14 13 14 13 14 13 14 13 14 13 14 14 13 14 14 14 13 14 14 15 15 13 14 14 14 14 14 14 14 14 14 14
 | 111 3 112 1 112 1 112 1 112 1 112 1 112 1 112 1 112 1 112 1 112 1 112 1 114 8 114
 | 118 7 110 7 110 7 110 7 110 7 110 7 111
 | 97 76 89 55 14 6 63 56 04 6 15 44 90 6 85 78 22 44 80 62 37 43 94 64 78 66 78 66 94 74 90 47 90 47 90 43 165 48 251 89 51 10 | 55 755 755 75 55 555 55 555 555 60 78 82 61 78 61 62 74 655 555 555 80 61 62 84 81 61 10 87 82 61 10 742 742 742 33 86 633 6523 86 6333 86 6333 653 86 | 80 pure 90 pure 91 90 92 9 93 73 4 843 7 722 6 694 4 744 9 733 7 722 7 722 7 722 7 722 9 733 7 722 9 733 9 733 9 731 4 671 4 671 4 671 4 712 4 555 45 555
 | 93 93 92 93 92 94 93 4 93 4 93 4 93 4 93 4 93 4 93 4 93 3 93 3 93 3 93 3 93 164 93 164 93 164
 | 3 499 305 309 309 309 309 304 288 309 309 309 304 288 41 465 311 305 7344 477 422 59 305 7344 477 422 488 411 655 584 49 49 304 477 422 242 49 49 311 555 743 577 743 556 | 484 484 538 538 453 533 538 402 384 533 402 384 384 384 402 392 384 397 397 364 397 393 397 595 393 6424 393 6424 | Image: system Image: s | 4277
3499
4222
418
3899
2411
3322
3233
236
4222
2511
3322
3233
236
4222
2511
3322
3233
6355
672
672
672
672
672
7733
6566
6517
752 | 3699 3699 2811 2255 278 278 275 265 394 198 373 3211 3777 287 4044 347 4044 3955 264 3955 4084 42444 | 1444
125
145
145
145
149
117
123
112
112
1123
110
109
95
1366
109
95
1366
109
95
1366
109
95
1227
126
83
3
1122
145
145
145
145
145
145
145
145
145
145 | 100 84 59 72 108 110 58 76 68 74 74 143 131 127 109 99 189 121 | 56 54 47 56 71 46 55 49 46 54 60 42 69 53 45 38 49 55 | pup SUP 24
4
6
6
5
1
4
0
28
26
33
10
17
17
24
14
35
28
29
18
22
17
27
 | 12 20 4 2 4 3 13 17 3 2 21 2 8 2 3 19 3 8 42 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia
Poland
Estonia | ₹ 20251 18033 18186 18782 18634 18063 19104 19569 19401 19674 18888 19135 20170 19929 20075 20201 19743 21153 22749 23061 | 3342 2977 2976 3311 2933 2672 2604 3049 315 3614 3256 3494 3221 3300 2648 3404 3252 3300 2648 3492 3300 2648 3495 3405 3405 3494 3252 3700 3643 3494 3250 3494 3250 3700 3612 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021
1968
2021
1968
2001
3198
2909
3198
3909
4183
4651 | 20202
18311
21844
205552
21411
2036
22244
1971
2037
2273
22566
2001
1521
2042
22485
22111
2042
22485
22111
2042
2155
22141
1521
2042
2255
2011
1521
2015
2255
2016
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017 | 1877 219 1955 204 185 201 185 201 185 201 185 201 185 201 190 190 190 190 190 190 190 188 206 206 1466 207 188 208 189 2266 1911 188 2266 1911 188 2266 191 138 192 193 193 | 4 155 144 155 144 155 145 160 147 133 15 197 145 100 147 133 15 197 141 177 142 160 155 157 144 177 144 177 155 155 155 155 155 1223 100 155 155 1223 13 155 15 1233 | 141 13 121 13 14 121 13 14 121 13 14 121 13 14 121 14 15 121 13 13 121 13 13 121 13 13 121 13 14 121 13 14 121 13 14 121 14 15 121 14 15 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14 121 14 14
 | 111 8 111 9 111 10 <t< td=""><td>111 7 110 7 110 7 110 7 110 7 110 7 110 6 110 6 110 6 110 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111</td><td>97 7(7) 89 5:2 814 6-6 63 5:0 80 6 81 7(7) 82 7(7) 835 7(7) 840 6 837 4:4 97 86 974 6:5 984 6:6 6:5 4:4 6:6 4:4 6:65 4:4 951 10 952 90 8:1 8:3</td><td>55 755 75 75 75 75 75 75 75 75 75 75 75 75 75 75 76 78 74 65 75 96 74 65 75 96 74 65 74 65 76 74 76 74 74 74 74 86 74 86 74 86 74 86 74 86 74 86 74 86 74 86 74 86
74 86 73 86 86 86 86 86 86 86 86 86</td><td>80 pue uny 90 pue uny 4 68-32 90 733 4 844 7 722 4 744 1 711 8 744 9 723 9 722 9 723 9 734 9 734 9</td></t<> <td>separation separation separation separation <t< td=""><td>3 499 305 309 305 305 309 305 305 304 48 46 44 466 311 555 733 44 44 465 55 55 733 44 47422 59 55 311 7626 7422 24 47422 24 311 7656 5773 315 57742 5742 316 66 7773 558 5742 5742</td><td>484 484 5333 5333 40 5333 5332 402 341 5333 401 5333 402 394 402 394 388 374 3933 374 3934 374 3935 5633 5635 5633 5635 5633 6415 5633 6425 6025</td><td>Image: style style</td><td>427
349
422
418
389
241
316
332
236
422
251
323
4422
251
440
289
315
672
773
656
672
773
656
517
7752
653</td><td>3699 3699 2811 2255 275 265 3944 208 1988 3733 5277 2777 3211 3217 2777 3477 2877 2877 3944 408 408 395 4788 395 4788 2288 559 559</td><td>1444
1255
1459
1459
1459
1459
1455
1459
1457
1455
1457
117
117
117
117
117
117
117
117
117
1</td><td>100
84
59
72
108
110
58
77
68
69
74
74
143
131
127
109
69
99
99
9189
121
186
150</td><td>56 54 47 56 71 65 49 43 46 54 60 42 69 53 45 38 49 55 62 45</td><td>44 66 51 40 28 18 26 33 10 177 199 24 14 35 28 28 18 26 17 199 24 14 35 28 29 18 22 27 167 17</td><td>12 20 4 2 3 17 3 21 2 8 3 3 19 3 8 42 31 33</td></t<></td> | 111 7 110 7 110 7 110 7 110 7 110 7 110 6 110 6 110 6 110 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 6 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111 7 111
 | 97 7(7) 89 5:2 814 6-6 63 5:0 80 6 81 7(7) 82 7(7) 835 7(7) 840 6 837 4:4 97 86 974 6:5 984 6:6 6:5 4:4 6:6 4:4 6:65 4:4 951 10 952 90 8:1 8:3 | 55 755 75 75 75 75 75 75 75 75 75 75 75 75 75 75 76 78 74 65 75 96 74 65 75 96 74 65 74 65 76 74 76 74 74 74 74 86 74 86 74 86 74 86 74 86 74 86 74 86 74 86 74 86 74 86 73 86 86 86 86 86 86 86 86 86 | 80 pue uny 90 pue uny 4 68-32 90 733 4 844 7 722 4 744 1 711 8 744 9 723 9 722 9 723 9 734 9 734 9
 | separation separation separation separation <t< td=""><td>3 499 305 309 305 305 309 305 305 304 48 46 44 466 311 555 733 44 44 465 55 55 733 44 47422 59 55 311 7626 7422 24 47422 24 311 7656 5773 315 57742 5742 316 66 7773 558 5742 5742</td><td>484 484 5333 5333 40 5333 5332 402 341 5333 401 5333 402 394 402 394 388 374 3933 374 3934 374 3935 5633 5635 5633 5635 5633 6415 5633 6425 6025</td><td>Image: style style</td><td>427
349
422
418
389
241
316
332
236
422
251
323
4422
251
440
289
315
672
773
656
672
773
656
517
7752
653</td><td>3699 3699 2811 2255 275 265 3944 208 1988 3733 5277 2777 3211 3217 2777 3477 2877 2877 3944 408 408 395 4788 395 4788 2288 559 559</td><td>1444
1255
1459
1459
1459
1459
1455
1459
1457
1455
1457
117
117
117
117
117
117
117
117
117
1</td><td>100
84
59
72
108
110
58
77
68
69
74
74
143
131
127
109
69
99
99
9189
121
186
150</td><td>56 54 47 56 71 65 49 43 46 54 60 42 69 53 45 38 49 55 62 45</td><td>44 66 51 40 28 18 26 33 10 177 199 24 14 35 28 28 18 26 17 199 24 14 35 28 29 18 22 27 167 17</td><td>12 20 4 2 3 17 3 21 2 8 3 3 19 3 8 42 31 33</td></t<> | 3 499 305 309 305 305 309 305 305 304 48 46 44 466 311 555 733 44 44 465 55 55 733 44 47422 59 55 311 7626 7422 24 47422 24 311 7656 5773 315 57742 5742 316 66 7773 558 5742 5742 | 484 484 5333 5333 40 5333 5332 402 341 5333 401 5333 402 394 402 394 388 374 3933 374 3934 374 3935 5633 5635 5633 5635 5633 6415 5633 6425 6025 | Image: style | 427
349
422
418
389
241
316
332
236
422
251
323
4422
251
440
289
315
672
773
656
672
773
656
517
7752
653 | 3699 3699 2811 2255 275 265 3944 208 1988 3733 5277 2777 3211 3217 2777 3477 2877 2877 3944 408 408 395 4788 395 4788 2288 559 559
 | 1444
1255
1459
1459
1459
1459
1455
1459
1457
1455
1457
117
117
117
117
117
117
117
117
117
1 | 100
84
59
72
108
110
58
77
68
69
74
74
143
131
127
109
69
99
99
9189
121
186
150 | 56 54 47 56 71 65 49 43 46 54 60 42 69 53 45 38 49 55 62 45 | 44 66 51 40 28 18 26 33 10 177 199 24 14 35 28 28 18 26 17 199 24 14 35 28 29 18 22 27 167 17 | 12 20 4 2 3 17 3 21 2 8 3 3 19 3 8 42 31 33 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia
Poland
Estonia
Croatia
Slovakia | ₹ 20251 18033 18186 18782 18634 18983 19104 19569 19674 18888 19135 20170 19929 20075 20201 19743 21153 23061 21886 23352 | 3342 2977 2976 3311 2933 2672 2604 3049 315 3614 3256 3494 3221 3300 2648 3404 3252 3300 2648 3492 3300 2648 3495 3405 3405 3494 3252 3700 3643 3494 3250 3494 3250 3700 3612 | 2759
1834
2032
1628
21628
2329
2511
2408
2864
2032
2150
1883
2546
2021
1968
2601
3198
2939
3909
34051
4267
5134 | 2020
183112
2184
2055
2141
2036
2024
2037
2037
2042
2042
2042
2042
2042
2048
2042
2048
2048
2048
2048
2015
1521
2042
2055
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2016
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017
2017 | 1877 219 1955 204 185 201 185 201 185 201 185 201 185 201 185 201 190 190 190 188 206 206 206 188 206 188 206 188 206 189 2266 1911 188 2266 1911 188 2266 1911 138 1255 137 137 | 44 155 144 155 144 155 160 144 17 133 177 133 177 142 199 16 121 155 122 155 123 155 124 155 155 125 155 125 155 125 155 125 155 125 155 123 155 123 155 123 155 123 155 123 155 123 155 123 155 123 155 123 155 123 155 123 155 123 155 123 155 133 155 155 | 141 1332 1332 14472 1332 14472 1332 14472 1332 14472 1332 1414 141 1332 152 141 1532 151 15332 151 154 1556 1556 132 1556 132 1513 122 1513 122
 | 111 8 111
 | 1118 7 110 7 110 7 110 7 110 7 110 7 110 7 110 7 110 6 110 6 111 7 111
 | 97 7(7) 89 52 89 52 14 6-6 63 56 14 6-6 15 44 190 6 885 70 22 44 90 6 337 42 97 86 94 6-778 6045 77 90 4 4251 86 51 10 52 90 81 82 | 55 755 755 74 753 755 75 755 755 76 787 787 74 755 755 75 755 755 74 755 755 74 765 747 75 766 747 755 76 747 755 755 76 747 725 747 70 722 744 747 70 722 747 755 | 80 pure p
 | 93 90 92 92 93 46 94 600 97 97 98 46 99 97 90 97 91 1 92 99 93 36 92 99 93 36 93 38 92 99 93 35 94 511 97 764 93 36 94 511 97 764 97 764 97 764 97 764 97 764 97 764 97 764 97 764 97 764 97 764 97 764 97 764 97 764 97 764 | 499 3000 499 3000 400 264 400 264 400 264 400 265 301 311 302 311 302
 311 302 311 302 311 302 311 303 355 304 311 305 311 305 311 305 311 | 4844 3 4844 4834 5332 49 5332 41 5332 341 401 402 341 341 341 341 341 341 341 341 341 341 341 341 341 341 341 341 341 359 359 3632 3632 3632 3632 3644 3684 3602 3602 3602 3612 3612 3612 3612 3612 3612 3612 3612 3612 3612 3612 | Image: style | 42773349
422414273349
42241423389
42251332232323233233233233223
6355672225153356722
63556725356533693 | 3699 3699 2811 2255 275 265 3944 208 1988 208 39344 208 3934 208 3934 208 3934 208 3944 347 287 408 2084 2887 4084 2687 4084 2687 408 267 3955 3944 408 2687 408 2687 408 2687 408 2687 408 2687 408 2687 408 2687 408 2687 408 424 2288 574 574 574 | 1444
1255
1455
1495
1499
1177
123
1111
103
100
955
1366
1099
1277
1266
83
1099
1227
1268
83
1122
1422
1422
1422
1422
1422
1422
142 | 100
84
59
72
78
68
100
58
77
68
69
74
74
74
143
131
127
109
69
99
99
99
189
121
186
150
182 | 56 54 47 56 71 55 49 43 46 54 60 42 69 53 45 38 49 55 62 45 76 | ul pur solution of the second | 12
20
4
3
3
13
17
3
2
2
1
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia
Poland
Estonia
Croatia
Slovakia
Lithuania
Hungary
Latvia | ₹ 20251 18033 18186 18782 18634 1904 19569 19401 19569 19401 19569 20075 20075 20075 20201 19743 21886 23061 21886 24500 25648 24500 26016 | 3342
2977
2976
3311
2933
2672
2604
2800
2604
2800
3049
3135
3614
3341
3345
3494
3300
2648
3494
3300
2648
3494
3300
2648
3495
3573
3762
3573
3651
3631 | 2759
1834
2032
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2150
2864
2021
1968
2039
2546
2039
4183
3909
4183
3909
4183
4651
4267
5134
55824
55824
55824 | 20200
1831
2184
2055
2141
2037
2224
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037 | 1877 219 195 204 185 201 195 204 185 201 187 190 190 190 190 190 190 190 190 190 190 188 190 188 190 | 4 155 144 155 144 155 155 160 147 133 155 155 155 160 147 133 155 199 141 177 142 160 15 177 142 160 15 177 14 177 14 175 15 122 16 15 17 144 17 144 17 144 17 144 | 14496 1550 1496 1332 1496 1332 1496 1332 1496 1332 1496 1332 1496 1496 1496 1332 1332 1332 1484 13337 129992 15663 159992 15639 159932 1513 1216 133 1216 133 1216 131 1216 131 1216 131 1216 131 1216 131 1216 131 1216 131 1216 131 131 12 131 12 131 12 131 12 131 12 131 13 131 13 131 13 131 13 131 13 <
 | 111 8 111 9 112 7 112 7 112 7 112 7 112 7 112 7 112 7 112 7 111 8 111
 | 1118 7 110 7 120 7 121 7 124 84 120 7 121 6 121 6 121 6 121 7 121 7 122 6 123 6 124 9 125 6 126 6 126 6 126 6 126 6 126 6 126 6 126 7 126 6 126 7 126 12 126 12 126 12 127 13 128 14 129 14 129 14 129 14 129 14 129 14 129 </td <td>997 7(7) 997 7(7) 998 55 14 64 63 55 04 63 15 44 115 44 115 44 115 44 115 44 122 44 800 63 917 8480 924 64 929 7 9394 64 947 78 9494 77 950 44 1052 94 81 82 94 7 94 75 95 100 94 12 94 14 94 14 94 14 94 14</td> <td>55 755 755 711 75 75 711 75 75 75 75 75 75 75 75 75 75 75 78 78 78 79 77 74 74 65 55 75 96 10 78 10 74 79 72 73 70 72 73 70 72 73 70 72 73 70 72 73 71 33 86 72 733 88 733 86 62 74 247 74 74 247 74 74 247 74</td> <td>80 pue uive 91 91 32 92 733 4 844 7 722 66 69 4 844 744 11 711 7 722 5 455 5 5 55 55 55 355 99 730 0 772 1 99 730 0 774 671 99 733 4 671 4 4 474 415 552 4 4 552 2 444 552 2 444 444 4 4555 7 7 88 4552
 4 444 444 444 444 444 444 444 444 4453 4453 4553 4553 4553 4553 4553 4553 4553 4533 4533 4533 4533 4533 4533 4533<td>93 90 94 600 97 611 98 90 99 90 90 90 90 90 91 600 92 90 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 164 93 164 94 94 94 94 94 94 94 94 94 94</td><td>499 3004 4284 3004 4284 3004 4284 3004 4284 3004 429 3004 467 4004 55 7333 3848 477 422 59 311 366 477 422 431 3004 422 59 33 480 477 422 411 76 422 241 477 422 41 76 422 241 431 166 55 5743 555 7433 555 5743 433 1355 555 5743 555 5743 555 5743 565 5743 575 575 575 575 575 575</td><td>484 484 5333 5333 4533 3402 5333 5402 341 5333 341 5333 341 5333 341 5333 341 3414 3938 3414 3922 4131 313 5566 313 3414 3937 7 3933 6422 313 6002 313 6002 314 6144 402 6144</td><td>Image: style style</td><td>42773349
422241
33899241
33893233
3236
332233232
422
2511
6355
652
6535
652
6535
6526
653
6536
653
6556
653
6536
653
653
653</td><td>3699 2815 2255 2655 2675 2655 394 208 3733 3733 3211 2775 2655 2775 2655 2777 3047 2877 2010 2777 4044 2877 2644 2887 2655 5592 265502 502</td><td>$\begin{array}{c} 144\\ 145\\ 145\\ 145\\ 149\\ 117\\ 123\\ 149\\ 117\\ 123\\ 149\\ 100\\ 95\\ 136\\ 109\\ 95\\ 136\\ 109\\ 127\\ 126\\ 136\\ 112\\ 122\\ 196\\ 130\\ 122\\ 161\\ 161\\ 161\\ 161\\ 161\\ 161\\ 161$</td><td>100
84
59
72
108
110
58
69
74
74
74
143
131
127
109
69
99
99
99
2121
186
150
182
182
7187</td><td>56 54 47 56 47 56 49 43 46 54 49 43 46 54 49 43 46 54 60 42 69 53 38 49 55 62 45 76 78 56 89</td><td>pue SQIN/NH 44
66
51
40
28
33
10
17
24
14
35
28
29
18
22
17
27
167
17
22
107
17
22
300
300</td><td>12 20 4 2 4 3 17 3 2 21 2 3 3 4 33 36 32 33 36 32 33 32 33 31</td></td> | 997 7(7) 997 7(7) 998 55 14 64 63 55 04 63 15 44 115 44 115 44 115 44 115 44 122 44 800 63 917 8480 924 64 929 7 9394 64 947 78 9494 77 950 44 1052 94 81 82 94 7 94 75 95 100 94 12 94 14 94 14 94 14 94 14 | 55 755 755 711 75 75 711 75 75 75 75 75 75 75 75 75 75 75 78 78 78 79 77 74 74 65 55 75 96 10 78 10 74 79 72 73 70 72 73 70 72 73 70 72 73 70 72 73 71 33 86 72 733 88 733 86 62 74 247 74 74 247 74 74 247 74 | 80 pue uive 91 91 32 92 733 4 844 7 722 66 69 4 844 744 11 711 7 722 5 455 5 5 55 55 55 355 99 730 0 772 1 99 730 0 774 671 99 733 4 671 4 4 474 415 552 4 4 552 2 444 552 2 444 444 4 4555 7 7 88 4552 4 444 444 444 444 444 444 444 444 4453 4453 4553 4553 4553 4553 4553 4553 4553 4533 4533 4533 4533 4533 4533 4533 <td>93 90 94 600 97 611 98 90 99 90 90 90 90 90 91 600 92 90 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 164 93 164 94 94 94 94 94 94 94 94 94 94</td> <td>499 3004 4284 3004 4284 3004 4284 3004 4284 3004 429 3004 467 4004 55 7333 3848 477 422 59 311 366 477 422 431 3004 422 59 33 480 477 422 411 76 422 241 477 422 41 76 422 241 431 166 55 5743 555 7433 555 5743 433 1355 555 5743 555 5743 555 5743 565 5743 575 575 575 575 575 575</td> <td>484 484 5333 5333 4533 3402 5333 5402 341 5333 341 5333 341 5333 341 5333 341 3414 3938 3414 3922 4131 313 5566 313 3414 3937 7 3933 6422 313 6002 313 6002 314 6144 402 6144</td> <td>Image: style style</td> <td>42773349
422241
33899241
33893233
3236
332233232
422
2511
6355
652
6535
652
6535
6526
653
6536
653
6556
653
6536
653
653
653</td> <td>3699 2815 2255 2655 2675 2655 394 208 3733 3733 3211 2775 2655 2775 2655 2777 3047 2877 2010 2777 4044 2877 2644 2887 2655 5592 265502 502</td> <td>$\begin{array}{c} 144\\ 145\\ 145\\ 145\\ 149\\ 117\\ 123\\ 149\\ 117\\ 123\\ 149\\ 100\\ 95\\ 136\\ 109\\ 95\\ 136\\ 109\\ 127\\ 126\\ 136\\ 112\\ 122\\ 196\\ 130\\ 122\\ 161\\ 161\\ 161\\ 161\\ 161\\ 161\\ 161$</td>
<td>100
84
59
72
108
110
58
69
74
74
74
143
131
127
109
69
99
99
99
2121
186
150
182
182
7187</td> <td>56 54 47 56 47 56 49 43 46 54 49 43 46 54 49 43 46 54 60 42 69 53 38 49 55 62 45 76 78 56 89</td> <td>pue SQIN/NH 44
66
51
40
28
33
10
17
24
14
35
28
29
18
22
17
27
167
17
22
107
17
22
300
300</td> <td>12 20 4 2 4 3 17 3 2 21 2 3 3 4 33 36 32 33 36 32 33 32 33 31</td> | 93 90 94 600 97 611 98 90 99 90 90 90 90 90 91 600 92 90 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 82 93 164 93 164 94 94 94 94 94 94 94 94 94 94 | 499 3004 4284 3004 4284 3004 4284 3004 4284 3004 429 3004 467 4004 55 7333 3848 477 422 59 311 366 477 422 431 3004 422 59 33 480 477 422 411 76 422 241 477 422 41 76 422 241 431 166 55 5743 555 7433 555 5743 433 1355 555 5743 555 5743 555 5743 565 5743 575 575 575 575 575 575 | 484 484 5333 5333 4533 3402 5333 5402 341 5333 341 5333 341 5333 341 5333 341 3414 3938 3414 3922 4131 313 5566 313 3414 3937 7 3933 6422 313 6002 313 6002 314 6144 402 6144
 | Image: style | 42773349
422241
33899241
33893233
3236
332233232
422
2511
6355
652
6535
652
6535
6526
653
6536
653
6556
653
6536
653
653
653 | 3699 2815 2255 2655 2675 2655 394 208 3733 3733 3211 2775 2655 2775 2655 2777 3047 2877 2010 2777 4044 2877 2644 2887 2655 5592 265502 502 | $\begin{array}{c} 144\\ 145\\ 145\\ 145\\ 149\\ 117\\ 123\\ 149\\ 117\\ 123\\ 149\\ 100\\ 95\\ 136\\ 109\\ 95\\ 136\\ 109\\ 127\\ 126\\ 136\\ 112\\ 122\\ 196\\ 130\\ 122\\ 161\\ 161\\ 161\\ 161\\ 161\\ 161\\ 161$ | 100
84
59
72
108
110
58
69
74
74
74
143
131
127
109
69
99
99
99
2121
186
150
182
182
7187 | 56 54 47 56 47 56 49 43 46 54 49 43 46 54 49 43 46 54 60 42 69 53 38 49 55 62 45 76 78 56 89 | pue SQIN/NH 44
66
51
40
28
33
10
17
24
14
35
28
29
18
22
17
27
167
17
22
107
17
22
300
300 | 12 20 4 2 4 3 17 3 2 21 2 3 3 4 33 36 32 33 36 32 33 32 33 31 |
| Spain
Italy
France
Luxembourg
Sweden
Malta
Austria
Finland
Ireland
Portugal
Netherlands
Slovenia
Belgium
Denmark
Germany
Greece
Cyprus
Czechia
Poland
Estonia
Croatia
Slovakia
Lithuania
Hungary | ₹ 20251 18033 18186 18782 18634 18069 18983 19104 19569 19401 19674 18888 19135 20170 19929 20075 20201 19743 21153 22749 23352 25648 24500 | 3342
2977
2976
3311
2933
2672
2604
2820
2606
3049
3135
33614
3341
3352
3494
3494
3494
3494
3494
3494
3405
2648
3405
2648
3405
2648
3405
2648
3405
2673
3572
3770
3762
3573
3572
3573
3522
3573
3522
3575
3522
3523
3522
3523
3522
3523
3522
3523
3522
3523
3522
3523
3522
3523
3522
3523
3522
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3523
3525
3523
3523
3525
3523
3523
3525
3523
3525
3523
3525
3523
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3525
3555
3555
3555
3555
3555
3555
3555
3555
3555
35555
35555
35555
355555
355555
3555555 | 2759
1834
2032
1628
1981
2329
2511
2408
2864
2193
2150
1883
2546
2021
1968
2021
3198
2039
3909
34183
4651
4267
5134
5520
6603
6604 | 20200
1831
2184
2055
2141
2037
2224
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2036
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037
2037 | 1877 219 1955 204 1955 204 1955 201 1955 201 1900 | 44 155 144 155 144 155 155 160 147 133 155 155 155 160 147 133 155 199 161 177 142 160 15 177 144 177 12 160 12 161 12 161 14 177 14 177 14 177 14 175 15 122 15 122 15 123 16 164 13 155 12 16 14 15 15 12 14 15 15 12 16 16 17 14 18 14 13 15 | 550 14496 332 14496 332 14496 332 14496 332 14496 333 14496 343 13484 3333 14496 3484 13333 3484 13333 3484 13333 3484 13337 3488 1663 9992 1991 33337 1216 336556 133 36664 1216 3133 1216 3143 1216 31533 1216 3143 1216 31533 1216 31613 12 31634 131 31634 131 31634 131 31634 131 31634 131 31634 131 31634 131 31634 131 31634 131 <t< td=""><td>111 8 111 9 112 7 112 7 112 7 112 7 112 7 112 7 112 7 112 7 111 8 111</td><td>1118 7 110 7 84 8 9391 8 9391 8 9391 8 9391 8 9391 8 9391 8 9391 8 336 6 680 9 74 6 6267 6 6267 6 6267 6 70064 11 9 9 9880 7 7770 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 9 </td></t<> <td>997 7(7) 889 5: 141 64: 663 5: 044 663 155 44 115 44 115 44 115 44 115 44 115 44 115 44 122 44
 14 64 14 64 12 44 12 14 14 12</td> <td>755 755 755 757 757</td> <td>Solution Solution Solution Solution<</td> <td>93 90 94 600 97 41 98 34 99 35 99 35 90 100 91 600 92 699 93 466 93 346 93 346 93 346 93 346 93 346 93 346 94 511 10 764 94 511 10 764 94 94 94 94 94 94 95 94 94 94 95 94 94 94 95 94 95 94 94 94 95 94 95 94 95 94 95 95 95</td> <td>33 499 300 4 284 284 4 284 284 4 284 284 4 285 300 4 486 311 5 55 733 4 474 422 5 55 733 4 474 422 4 474 422 5 5 733 4 474 422 4 474 422 5 5 737 4 474 486 3 355 5 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 5</td> <td>484 484 5333 400 384 5333 400 384 400 384 400 384 400 384 400 400 200 344 400 400 21 397 32 4131 30 374 33 374 33 642 33 642 34 600 35 616 36 612 36 612 36 612 36 612 37 595 36 633 37 595 36 613 37 595 38 600 39 614 39 614 39 614 39 614 39 614 39 614</td> <td>I 452 452 3300 3 3403 3 3403 3 3403 3 3403 3 3403 3 3473 3 3473 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3696 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3673 3 3673</td> <td>42773349
422241
33899241
33893233
3236
332233232
422
2511
6355
652
6535
652
6535
6526
653
6536
653
6556
653
6536
653
653
653</td> <td>3699 2815 225 265 334 200 334 200 334 200 334 200 3215 200 33733 3211 3211 200 33733 3211 3211 200 3347 200 3477 200 395 200 5599 574424 200 502 2010 1000</td> <td>1444
1255
1457
1499
1177
123
111
100
95
1366
109
95
127
126
109
122
126
130
122
126
130
122
162
162
162
162
162
163
163
152
161</td> <td>100
84
59
72
108
110
58
77
68
69
74
143
131
127
74
143
131
127
109
69
99
121
189
150
150
182
237</td> <td>56 54 47 56 71 46 55 49 43 60 42 69 53 45 53 45 53 45 56 76 78 56</td> <td>pue SQINAL ACT ACT ACT ACT ACT ACT ACT ACT ACT ACT</td> <td>12 20 4 3 13 17 3 2 2 8 2 3 17 3 2 13 19 3 8 42 31 33 36 32 33 36 32 33</td> | 111 8 111 9 112 7 112 7 112 7 112 7 112 7 112 7 112 7 112 7 111 8 111
 | 1118 7 110 7 84 8 9391 8 9391 8 9391 8 9391 8 9391 8 9391 8 9391 8 336 6 680 9 74 6 6267 6 6267 6 6267 6 70064 11 9 9 9880 7 7770 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 8 9 9 9 9
 | 997 7(7) 889 5: 141 64: 663 5: 044 663 155 44 115 44 115 44 115 44 115 44 115 44 115 44 122 44 14 64 14 64 12 44 12 14 14 12 | 755 755 755 757 757 | Solution Solution Solution Solution<
 | 93 90 94 600 97 41 98 34 99 35 99 35 90 100 91 600 92 699 93 466 93 346 93 346 93 346 93 346 93 346 93 346 94 511 10 764 94 511 10 764 94 94 94 94 94 94 95 94 94 94 95 94 94 94 95 94 95 94 94 94 95 94 95 94 95 94 95 95 95 | 33 499 300 4 284 284 4 284 284 4 284 284 4 285 300 4 486 311 5 55 733 4 474 422 5 55 733 4 474 422 4 474 422 5 5 733 4 474 422 4 474 422 5 5 737 4 474 486 3 355 5 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 77 5 5 5 | 484 484
5333 400 384 5333 400 384 400 384 400 384 400 384 400 400 200 344 400 400 21 397 32 4131 30 374 33 374 33 642 33 642 34 600 35 616 36 612 36 612 36 612 36 612 37 595 36 633 37 595 36 613 37 595 38 600 39 614 39 614 39 614 39 614 39 614 39 614 | I 452 452 3300 3 3403 3 3403 3 3403 3 3403 3 3403 3 3473 3 3473 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3696 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3674 3 3673 3 3673 | 42773349
422241
33899241
33893233
3236
332233232
422
2511
6355
652
6535
652
6535
6526
653
6536
653
6556
653
6536
653
653
653 | 3699 2815 225 265 334 200 334 200 334 200 334 200 3215 200 33733 3211 3211 200 33733 3211 3211 200 3347 200 3477 200 395 200 5599 574424 200 502 2010 1000 | 1444
1255
1457
1499
1177
123
111
100
95
1366
109
95
127
126
109
122
126
130
122
126
130
122
162
162
162
162
162
163
163
152
161 | 100
84
59
72
108
110
58
77
68
69
74
143
131
127
74
143
131
127
109
69
99
121
189
150
150
182
237 | 56 54 47 56 71 46 55 49 43 60 42 69 53 45 53 45 53 45 56 76 78 56 | pue SQINAL ACT | 12 20 4 3 13 17 3 2 2 8 2 3 17 3 2 13 19 3 8 42 31 33 36 32 33 36 32 33 |

Fig. 1 Age-standardised death (A) and DALY (B) rates (per 100 000 inhabitants) by the Level 2 causes for the European Union and for each country in 2019. Footnote (to be included next to the figure)—Cells in green (or lighter grey) have a rate statistically significantly lower than EU, red (or darker) higher and yellow (or medium grey) without statistically significant differences

	AS Death rate	Ð	AS YLL rate		AS YLD rate		AS DALY rate		Life expectancy	ncy	Health-adjusted life expectancy	sted life
	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)
European Union	465.8 (451.2; 480.9)	-8.8 (-11. <i>7;</i> -5.9)	9564 (9158; 9997)	-12 (-15.7; -8.1)	10,687 (7908; 13,858)	0.6 (-0.1; 1.2)	20,251 (17,408; 23,514)	-5.8 (-8; -3.7)	81.0 (80.6; 81.3)	1.4 (1.0; 1.9)	69.8 (66.6; 72.7)	1.2 (0.7; 1.6)
Austria	420.8 (413.4; 428.8)	-11.2 (-12.9; -9.4)	8360 (8154; 8584)	-14.9 (-17.2; -12.5)	10,744 (7927; 13,927)	-0.4 (-2; 1.2)	19,104 (16,292; 22,253)	-7.3 (-9.2; -5.6)	82.2 (82; 82.3)	1.7 (1.4; 2)	70.6 (67.2; 73.6)	1.6 (1.2; 1.9)
Belgium	449.5 (439.6; 460.2)	-9.4 (-11.6; -7.2)	9129 (8837; 9453)	-12.5 (-15.4; -9.4)	11,041 (8083; 14,321)	-2.1 (-3.7; -0.3)	20,170 (17,230; 23,435)	-7.1 (-9; -5.1)	81.4 (81.2; 81.6)	1.5 (1.2; 1.8)	69.7 (66.3; 72.8)	1.5 (1.1; 2)
Bulgaria	894.8 (744.3; 1070.7)	-7.1 (-23.7; 11)	19,339 (15,632; 23,799)	-9.4 (-27.9; 11.4)	10,036 (7413; 12,976)	0.3 (-1.5; 2.3)	29,375 (24,710; 34,547)	-6.3 (-18.7; 8)	73.3 (70.9; 75.7)	1.4 (-2; 4.9)	64.6 (61.4; 67.6)	1.3 (-1.9; 4.3)
Croatia	591.3 (486.8; 714.9)	-14.2 (-29.4; 3.6)		-16.7 (-33.4; 3.5)	10,274 (7607; 13,342)	0.2 (-2.1; 2.5)	21,886 (18,21 <i>9</i> ; 26,054)	-9.5 (-19.5; 2)	78.7 (76.5; 80.8)	2.4 (-0.4; 5.2)	68.2 (64.8; 71.5)	2 (-0.5; 4.2)
Cyprus	519.4 (480.7; 563.4)	-14.4 (-21; -7.1)	9235 (8394; 10,194)	-12.4 (-20.6; -3)	10,508 (7709; 13,612)	0.4 (-1.1; 1.7)	19,743 (16,838; 22,880)	-6 (-10.7; -1.4)	80.8 (80; 81.6)	1.6 (0.6; 2.6)	69.9 (66.7; 72.9)	1.4 (0.5; 2.3)
Czechia	541 (457.8; 638.7)	-12.1 (-25.5; 3.6)	10,745 (8899; 12,953)	-15.2 (-29.7; 2.2)	1 0,409 (7680; 1 3,558)	0.2 (-1.8; 2.3)	21,153 (17,813; 24,971)	-8.2 (-16.7; 1.5)	79.5 (77.6; 81.3)	2.1 (-0.4; 4.4)	68.6 (65.1; 71.7)	1.7 (-0.4; 3.6)
Denmark	462.4 (449.3; 476.6)	-13.2 (-15.9; -10.5)	9162 (8798; 9566)	-14.9 (-18.4; -11.1)	10,768 (7956; 13,905)	-0.1 (-1.6; 1.6)	19,929 (17,111; 23,155)	-7.5 (-10; -5.2)	81.1 (80.8; 81.4)	2 (1.6; 2.4)	69.9 (66.7; 72.8)	1.7 (1.3; 2.2)
Estonia	584.3 (477.6; 707.2)	-12.8 (-28.8; 6)	13,026 (10,488; 16,078)	-15.4 (-32; 4.1)	1 0,035 (7400; 1 3,058)	-0.3 (-2.5; 1.8)	23,061 (19,316; 27,134)	-9.5 (-19.9; 2.3)	78 (75.6; 80.5)	2.4 (-0.9; 5.6)	68.1 (64.7; 71.4)	2.2 (-0.7; 5)
Finland	428.4 (414.9; 443.1)	-11.6 (-14.5; -8.5)	8765 (8419; 9144)	-15.4 (-18.9; -11.7)	10,805 (7991; 14,005)	-1.1 (-2.7; 0.6)	19,569 (16,724; 22,872)	-8.1 (-10.5; -5.9)	81.9 (81.5; 82.2)	1.8 (1.3; 2.3)	70.3 (67; 73.3)	1.8 (1.3; 2.3)
France	387.5 (380.3; 395.2)	-10.7 (-12.5; -8.9)	8282 (8061; 8526)	-13 (-15.5; -10.4)	10,499 (7719; 13,653)	0 (-1.8; 2)	18,782 (16,017; 21,919)	-6.2 (-8.2; -4.2)	82.9 (82.7; 83.1)	1.6 (1.3; 1.8)	71.5 (68.1; 74.5)	1.3 (0.9; 1.7)
Germany	462.5 (455.3; 471.1)	-5.2 (-6.7; -3.4)	9126 (8946; 9330)	-8.2 (-10.1; -6.2)	10,949 (8072; 14,255)	0.7 (-1.8; 3.2)	20,075 (17,158; 23 315)	-3.6 (-5.3; -1.7)	81.2 (81; 81.4)	0.9 (0.6; 1.1)	69.7 (66.4; 72.7)	0.6 (0.1; 1)

	AS Death rate	a	AS YLL rate		AS YLD rate		AS DALY rate		Life expectancy	cy	Health-adjusted life expectancy	ted life
	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)
European Union	465.8 (451.2; 480.9)	-8.8 (-11.7; -5.9)	9564 (9158; 9997)	-12 (-15.7; -8.1)	10,687 (7908; 13,858)	0.6 (-0.1; 1.2)	20,251 (17,408; 23,514)	-5.8 (-8; -3.7)	81.0 (80.6; 81.3)	1.4 (1.0; 1.9)	69.8 (66.6; 72.7)	1.2 (0.7; 1.6)
Greece	472.9 (461.8; 485.2)	-4.8 (-7.2; -2.3)	9543 (9206; 9929)	-6.1 (-9.6; -2.3)	10,658 (7853; 13,819)	-0.5 (-2.2; 1.3)	20,201 (17,423; 23,370)	-3.2 (-5.4; -1)	80.9 (80.7; 81.2)	0.7 (0.3; 1)	69.9 (66.7; 72.7)	0.7 (0.2; 1.1)
Hungary	667.5 (566.5; 785.6)	-13.1 (-26.1; 2.2)	14,296 (11,873; 17,181)	-15.9 (-30.1; 1)	10,204 (7532; 13,215)	0.4 (-1.6; 2.4)	24,500 (20,800; 28,629)	-9.8 (-18.7; 0.8)	76.6 (74.6; 78.6)	2.5 (-0.3; 5.1)	66.8 (63.6; 69.9)	2.1 (-0.2; 4.2)
Ireland	430.5 (416.4; 446)	-9.7 (-12.9; -6.4)	8320 (7935; 8752)	-14.5 (-18.6; -10.1)	11,081 (8177; 14,373)	0.2 (-1.5; 2)	19,401 (16,512; 22,745)	-6.7 (-9.4; -4.2)	82 (81 <i>.7;</i> 82.4)	1.5 (1.1; 2)	70.4 (67; 73.3)	1.3 (0.7; 1.8)
ltaly	386.8 (383.4; 390.1)	-9.2 (-10.1; -8.4)	7439 (7344; 7527)	-11.5 (-12.7; -10.4)	10,746 (7879; 14,084)	0.1 (-0.6; 0.8)	18,186 (15,294; 21,486)	-5 (-6.1; -4)	83.1 (83; 83.2)	1.2 (1.1; 1.4)	71.2 (67.8; 74.3)	1 (0.9; 1.2)
Latvia	685.3 (596.3; 797.8)	-15.7 (-26.6; -1.9)	15,938 (13,622; 18,804)	-19.9 (-31.5; -5.8)	10,078 (7427; 13,078)	-1 (-2.8; 0.9)	26,016 (22,399; 30,171)	-13.5 (-21.6; -3.9)	75.9 (73.8; 77.7)	3.5 (0.8; 6.1)	66.3 (63.2; 69.2)	3.3 (0.9; 5.6)
Lithuania	666.1 (565.5; 780)	-18.5 (-30.7; -4.5)	15,538 (13,039; 18,462)	-22.8 (-35; -8.1)	10,111 (7490; 13,073)	-2.1 (-4; -0.1)	25,648 (21,935; 29,654)	-15.8 (-24; -5.9)	76.2 (74.1; 78.3)	4.1 (1.2; 7)	66.6 (63.3; 69.6)	4 (1.4; 6.4)
Luxembourg	389.2 (353.4; 432.3)	-16.8 (-24.7; -7.4)	7794 (6939; 8847)	-16 (-25.7; -4.5)	10,840 (8014; 14,065)	-0.1 (-2; 1.8)	18,634 (15,642; 22,023)	-7.4 (-12.3; -1.9)	82.9 (81.8; 83.9)	2.3 (0.9; 3.7)	71 (67.5; 74.1)	1.9 (0.6; 3.1)
Malta	400.4 (365.8; 438.7)	-13.1 (-20.3; -5.3)	8350 (7400; 9502)	-12.7 (-22.6; -1.1)	10,633 (7845; 13,777)	-0.2 (-1.7; 1.3)	18,983 (16,094; 22,345)	-6.1 (-11.2; -0.6)	82.6 (81.6; 83.5)	1.8 (0.7; 3)	71.1 (67.7; 74.1)	1.5 (0.5; 2.6)
Netherlands	443.1 (432.3; 454.7)	-6.6 (-8.9; -4.1)	8503 (8200; 8844)	-9 (-12.3; -5.4)	10,385 (7710; 13,439)	2.3 (0.4; 4.5)	18,888 (16,190; 22,000)	-3.1 (-5.4; -0.8)	81.7 (81.5; 82)	2.1 (-0.2; 4.4)	70.6 (67.5; 73.4)	0.4 (-0.1; 0.9)
Poland	583.8 (504.2; 672.3)	-11.2 (-23.5; 2.1)	12,787 (10,894; 14,824)	-14.5 (-27.1; -0.5)	9963 (7364; 12,907)	0.1 (-0.7; 0.8)	22,749 (19,421; 26,563)	-8.7 (-16.6; -0.2)	78.1 (76.3; 79.9)	1.8 (1.5; 2.2)	68.1 (64.8; 71.2)	1.9 (-0.1; 3.8)
Portugal	439.9 (429.4; 451.3)	-12 (-14.3; -9.6)	8774 (8463; 9122)	-15.3 (-18.4; -11.8)	10,900 (8009; 14,120)	-2.2 (-3.8; -0.8)	19,674 (16,845; 22,930)	-8.5 (-10.7; -6.5)	81.7 (81.5; 82)	1.8 (1.5; 2.2)	70.2 (66.8; 73.2)	2 (1.6; 2.4)

Table 1 (continued)

	AS Death rate	Ð	AS YLL rate		AS YLD rate		AS DALY rate	Ð	Life expectancy	усу	Health-adjusted life expectancy	sted life
	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)
European Union	465.8 (451. <i>2;</i> 480.9)	-8.8 (-11.7; -5.9)	9564 (9158; 9997)	-12 (-15.7; -8.1)	10,687 (7908; 13,858)	0.6 (-0.1; 1.2)	20,251 (17,408; 23,514)	-5.8 (-8; -3.7) 81.0 (80.6; 81.3)	81.0 (80.6; 81.3)	1.4 (1.0; 1.9) 69.8 (66.6; 72.7)	69.8 (66.6; 72.7)	1.2 (0.7; 1.6)
Romania	716.5 (611.7; 835.4)	716.5 (611.7; -12.2 (-25.1; 835.4) 2.2)	16,199 (13,757; 19,117)	-14.6 (-27.5; 0.5)	9844 (7318; 12,819)	0.1 (-2; 2.2)	26,044 (22,457; 29,967)	-9.6 (-18.4; 0.7)	75.5 (73.5; 77.5)	2.4 (-0.3; 5)	66.4 (63.3; 69.2)	2.1 (-0.3; 4.4)
Slovakia	623.9 (511.6; 756.9)	-12.6 (-28.6; 6)	13,208 (10,559; 16,428)	-15 (-32.1; 5.3)	10,144 (7480; 13,113)	0 (-2.1; 2.1)	23,352 (19,472; 27,684)	-9.1 (-19.4; 3.3)	77.6 (75.2; 79.9)	2.3 (-0.8; 5.4)	67.6 (64.1; 70.8)	2 (-0.7; 4.5)
Slovenia	447.4 (362.1; 560.3)	-14.2 (-30.3; 6.9)	9023 (7218; 11,474)	-16.2 (-32.7; 6.4)	10,112 (7485; 13,119)	-2.5 (-4.4; -0.8)	19,135 (15,775; 23,040)	-9.5 (-18.5; 2.1)	81.4 (78.9; 83.7)	2.1 (-1; 5)	70.4 (66.7; 73.9)	2.2 (-0.6; 4.5)
Spain	385.9 (378.7; 393.6)	385.9 (378.7; -8.9 (-10.6; -7) 7570 (7372; 393.6) 7792)	7570 (7372; 7792)	-11.4 (-13.8; -8.8)	10,463 (7734; 1.3 (-0.5; 3.1) 13,596)	1.3 (-0.5; 3.1)	18,033 (15,282; 21,170)	-4.5 (-6.3; -2.6)	83.1 (82.9; 83.3)	1.2 (1; 1.5)	71.6 (68.3; 74.5)	0.9 (0.5; 1.3)
Sweden	397.9 (393.1; -8.5 (-9.9; 403) -7.2)	-8.5 (-9.9; -7.2)	7595 (7477; 7723)	-10.2 (-11.8; -8.5)	10,474 (7727; 0.9 (-0.5; 2.2) 13,605)	0.9 (-0.5; 2.2)	18,069 (15,379; 21,133)	-4.1 (-5.5; -2.8)	82.8 (82.7; 83)	1.2 (1; 1.4)	71.4 (68.1; 74.3)	0.9 (0.6; 1.2)

 Table 1 (continued)

10 to 14

5 to 9

1 to 4 <1 year

150 000




Fig. 2 Disability adjusted life years (DALYs) per 100,000 inhabitants, split into Years of life lost (YLL) and Years lived with disability (YLD), by sex and age group in the European Union in 2019. The error bars indicate the 95% uncertainty interval around the DALYs estimates

DALYs (YLDs + YLLs) per 100,000 general population (95% CI)

H

⊪

50 000

Н

H

Figure 1A and B show the age-standardised death and DALY rates, respectively, for the EU and each EU country in 2019, for all Level 2 causes, comparing each country with the EU. Causes had different patterns across EU countries. For example, for HIV/AIDS and sexually transmitted infections, Latvia and Portugal had the highest age-standardised death and DALY rates, with more than five times the EU. The contribution of fatal and non-fatal components of age-standardised DALY rates varied substantially across Level 2 causes (Fig. 3A). For neoplasms and cardiovascular diseases, YLLs contributed more than YLDs, while for musculoskeletal and mental disorders, the total DALYs were almost exclusively YLDs.

100 000

50 000

Figure 3B highlights the relative change in age-standardised YLL, YLD and DALY rates between 2010 and 2019 for Level 2 causes. Age-standardised YLL rates declined for all causes except for mental disorders (14.5% increase) and skin and subcutaneous diseases (2.6% increase), while Level 2 causes were quite evenly split between increases and decreases for age-standardised YLD rates. The largest decreases in age-standardised DALY rates were observed for HIV/AIDS and sexually transmitted diseases (-19.2%) and transport injuries (-19.1%). On the other hand, only diabetes and kidney diseases showed a significant increase (3.5%) for age-standardised DALY rates in the EU between 2010 and 2019, mainly due to the age-standardised YLD rate increase. Finally, it is worth mentioning that mental disorders showed a non-significant increase for age-standardised DALY rates between 2010 and 2019 and this increase was mainly due to YLL rates, although there was also an increase in age-standardised YLD rates.

100 000

150 000

Discussion

This study presents an overview of the state of health of the EU-27 and individual Member States in 2019, comparing the findings with data from 2010 to examine changes over the last decade. The results indicate that most countries experienced a significant, albeit varied, reduction in all-cause, age-standardised mortality and YLL rates over this period, although this pattern differed by country and region. During this time period, there were no substantial changes in all-cause agestandardised YLD rates, with the increase in the Netherlands being the most notable. The EU all-cause,




Fig. 3 Age-standardised YLL, YLD and DALY rates in 2019 (A), as well as changes (in %) between 2010 and 2019 (B) for the Level 2 causes in the European Union

age-standardised DALY rate fell by 5.8% over this period, mirroring global trends [15].

The observed variability in all-cause age-standardized death rates across countries in 2019 indicates that there are geographical clusters of mortality in the EU. The pattern of mortality burden clusters with a clear geographical variation across the EU was also observed for life expectancy rates and HALE measures. This pattern has been previously highlighted [13]. However, despite recent progress to reduce these differences, its persistence suggests that improvements may not continue uniformly across the EU without enhanced, combined and coordinated efforts to address a wide range of inequalities across health determinants, including socioeconomic factors.

Neoplasms and cardiovascular diseases were the leading causes for the burden of disease in the EU in 2019; both are attributable to the behavioural risk factors and depend on early diagnosis, treatment and management of risk factors. Inherently, these are among the costliest diseases for EU countries [24]. Additionally, with population ageing, NCDs are expected to increase over time and represent a greater proportion of overall deaths with higher mortality rates associated with cancer and cardiovascular disease relative to communicable diseases [25]. A recent analysis of changes in mortality and disability, comparing data from the GBD 1990-2019, confirmed this trend, finding that there has been an overall increase in disease burden among older Europeans during this time period, primarily driven by cardiovascular diseases [26]. These changes have not been homogeneous across the EU. As structures and systems take time to adapt to such changes, it suggests that existing differences may magnify if intervention strategies are not urgently introduced. Examining age-standardised DALY due to cancer, rates in the EU were between those of China (higher rate) and the United States of America (lower rate) [27]. EU countries had an estimated cancer burden of 4 million new cases annually in 2020, with cancer disproportionately affecting older Europeans and those living in Eastern EU Member States [28]. Future interventions must be designed to address the main drivers of NCDs, including population ageing, changes in population structure, and improvements in population-level risk factors, also considered in the Europe's Beating Cancer Plan. These must also address reasons for important differences across European regions. For example, despite the existence of cancer screening programmes across EU countries, differences in uptake of cancer screening varies according to socioeconomic factors; inequalities including lower household income, higher unemployment, and lower levels of educational attainment are associated with reduced uptake, especially in Eastern EU member states [29]. A similar trend is seen for cardiovascular diseases. EU member states with lower income levels and greater degrees of socioeconomic inequalities have disproportionately higher incidence rates and a greater burden of cardiovascular disease [30].

In this study, age-standardised death rates between countries varied widely by disease. For example, the results draw attention to the preventable high rates of self-harm and interpersonal violence across the EU in 2019. These mainly affected younger age groups. Although rates vary across the EU, we observed a geographical pattern with higher rates in the Baltic region. These differences in self-harm have been shown previously and likely relate to differences in the burden of mental disorders across the EU [31]. Baltic countries have historically had the highest rates of alcohol-related mortality and suicide, as well as a high burden of mental and behavioural disorders [32].

Infectious diseases, in general, represented a small share of age-standardised death rates until 2019, presenting an optimistic scenario regarding these most preventable diseases. There was, however, considerable heterogeneity in age-standardised death rates for some infectious diseases such as HIV and sexually transmitted infections, which despite overall low rates, had prominent outliers with relatively high rates in Latvia and Portugal. This highlights the importance of national preventive programmes that tackle the different transmission pathways, alongside with strengthening of surveillance systems [33].

Besides this heterogeneity, such infectious diseases showed an increased age-standardised YLL rate. This will be difficult to overcome without tailored health policies as the incidence of HIV is still increasing in several EU countries [34]. Moreover, infectious diseases are likely to represent a growing share of total disease burden following the COVID-19 pandemic, and will likely be of great importance in future GBD revisions.

Regarding DALYs, remarkable regional differences were found in cardiovascular diseases, self-harm and transport injuries, which were significantly higher in Eastern EU countries. Mental disorders were the fourth highest cause of age-standardised DALY rates and did not show a decrease over recent years. In fact, they showed a nonsignificant increase, mainly due to a remarkable increase in YLL. These conditions also represent one of the leading causes of YLD, which has been rising over recent years and has increased even more following the COVID-19 pandemic [35, 36]. Additionally, self-harm and interpersonal violence may also be linked to mental disorders, as an example of interacting causes. Thus, viewed as a whole, mental health disorders and other related possible outcomes such as self-harm and mortality linked to mental disorders, deserve special attention in line with WHO priorities [37].

The age-standardised YLD estimates generated by the GBD 2019 study show slight variation over time and across geographic areas and are subject to large levels of uncertainty. The former is mainly driven by the fact that the GBD severity distributions do not vary over time and space [38], essentially reducing differences in YLD rates to differences in the underlying prevalence estimates. Since prevalence data are typically sparser and more uncertain than mortality data, the modelled prevalence estimates further tend to smooth out temporal and spatial heterogeneity. In parallel, EU countries would need to improve the quality and performance of their health information systems, strengthening and integrating data

available through disease registers, claims data, primary care data, hospital discharge data and health surveys.

Strengths and limitations

This study is important and timely as it reflects the state of health in the EU prior to a number of major changes, including the COVID-19 pandemic and Brexit (the departure of the UK from the EU), and therefore will likely be important for policy-makers to understand the state of health of Europe at this pivotal moment in time. Although the UK is not included in the analysis and that potential adverse effects of Brexit on the health of the UK have been discussed [39], less is known about how it could impact the remaining EU-27. To date, there has been wide variation in the resilience and responses of health systems and governments to the pandemic across the EU, which replicates many of the regional variations presented in this study of the state of health of the EU. Comparing the results of this study with post-pandemic and post-Brexit GBD data will therefore be crucial to assess the impact of these 'shocks' on the health of EU citizens. Moreover, it could be pivotal for policy makers to address in future studies. Another strength of this study is that it provides estimates at the national level for EU countries for which burden of disease studies are lacking or are scarce and can support priority setting and resource allocations. This study used estimates provided by the GBD 2019 study and hence shares some limitations with other GBD studies, predominantly related mostly to the availability and quality of primary data, in particular for morbidity, which might not be homogeneous across EU countries. Moreover, there are some limitations pertaining to this paper related to: (1) the study design as it is a descriptive study, does not aim to estimate the effect of EU level policies; (2) timeline (as it provides an overall EU-level assessment across 10 years and excludes in-depth national assessment taking into account the year of accession to the EU); and (3) data availability. In addition, GBD metrics apply the same disability weights for all countries and regions. Such limitations have been widely discussed in the literature [15, 38].

Regarding the age-standardisation, it is also essential to highlight that while it is essential to ensure a global and comparable age standardisation, the used world standard population by GBD instead of a European standard population may change the ranking of causes [40].

Conclusions

In conclusion, although population health in the EU has been improving, large differences between countries persist. Health outcomes remain much better in Western or Southern Europe (e.g. Spain, Italy or France) than in Central and Eastern Europe (e.g. Bulgaria or Romania) or the Baltic states (e.g. Latvia or Lithuania). NCDs, particularly neoplasms and cardiovascular diseases continue to be the leading causes of disease burden. This study suggests that addressing the prevalence and incidence of diseases and injuries should be a priority for EU health policy makers, emphasising reducing health inequalities across the block. Attention must be paid to specific causes, including mental disorders, given their impact on YLD [41]. This study highlights that there are many opportunities for mutual learning among otherwise similar EU countries with different patterns of disease and injury.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12889-024-18529-3.

Supplementary Material 1.

Acknowledgements

The authors would like to acknowledge the networking support from COST Action CA18218 (European Burden of Disease Network), supported by COST (European Cooperation in Science and Technology). This article was supported by National Funds through FCT - Fundação para a Ciência e a Tecnologia, I.P., within CINTESIS, R&D Unit (reference UIDB/4255/2020).

GBD 2019 EU State of Health Collaborators

João Vasco Santos, MD,^{1,2} Alicia Padron-Monedero, PhD,³ Boris Bikbov, MD,⁴ Diana Alecsandra Grad, BA,^{5,6} Dietrich Plass, DrPH,⁷ Enkeleint A Mechili, PhD,^{8,9} Federica Gazzelloni, BSc,¹⁰ Florian Fischer, PhD,¹¹ Gerhard Sulo, PhD,¹² Che Henry Ngwa, MSc,¹³ Prof Isabel Noguer-Zambrano, PhD,³ Prof José L Peñalvo, PhD,^{14,15} Juanita A Haagsma, PhD,¹⁶ Katarzyna Kissimova-Skarbek, PhD,¹⁷ Lorenzo Monasta, DSc,¹⁸ Nermin Ghith, PhD,¹⁹ Prof Rodrigo Sarmiento-Suárez, MPH, 20,3 Rok Hrzic, MSc, 21 Romana Haneef, PhD, 22 Rónán O'Caoimh, PhD,^{23,24} Sarah Cuschieri, PhD,²⁵ Prof Stefania Mondello, NA,²⁶ Zubair Kabir, PhD,²⁷ Cristiana Abbafati, PhD,²⁸ Hassan Abolhassani, PhD,^{29,30} Victor Adekanmbi, PhD,³¹ Keivan Ahmadi, PhD,³² Sepideh Ahmadi, PhD,³³ Prof Adel Al-Jumaily, PhD,^{34,35} Prof François Alla, PhD,³⁶ Jordi Alonso, MD,^{37,38} Prof Robert Ancuceanu, PhD,³⁹ Catalina Liliana Andrei, PhD,⁴⁰ Prof Tudorel Andrei, PhD,⁴¹ Sofia Androudi, PhD,⁴² Prof Josep M Antó, MD,^{43,44} Seth Christopher Yaw Appiah, PhD,^{45,46} Olatunde Aremu, PhD,⁴⁷ Benedetta Armocida, MSc,⁴ Prof Johan Ärnlöv, PhD,^{49,50} Ashokan Arumugam, PhD,^{51,52} Sameh Attia, MSc,⁵³ Avinash Aujayeb, MBBS, 54 Prof Marcel Ausloos, PhD, 55,41 Prof Jose L Ayuso-Mateos, PhD,^{56,57} Prof Maciej Banach, PhD,^{58,59} Prof Till Winfried Bärnighausen, MD,^{60,61} Francesco Barone-Adesi, PhD,⁶² Sandra Barteit, PhD,⁶³ Sanjay Basu, PhD,^{64,32} Prof Bernhard T Baune, PhD,^{65,66} Massimiliano Beghi, MD,⁶⁷ Luis Belo, PhD,^{68,69} Derrick A Bennett, PhD,⁷⁰ Prof Antonio Biondi, PhD,⁷¹ Mahdi Bohluli, PhD,^{72,73} Israel Júnior Borges do Nascimento, MD,^{74,75} Nicola Luigi Bragazzi, PhD,⁷⁶ Tasanee Braithwaite, PhD,^{77,78} Prof Hermann Brenner, MD,⁷⁹ Danilo Buonsenso, MD,^{80,81} Prof Reinhard Busse, PhD,⁸² Prof Daniela Calina, PhD,⁸³ Giulia Carreras, PhD,⁸⁴ Márcia Carvalho, PhD,^{85,69} Giulio Castelpietra, PhD,^{86,87} Prof Alberico L Catapano, PhD,^{88,89} Maria Sofia Cattaruzza, PhD,⁹⁰ Joht Singh Chandan, MFPH,⁹¹ Periklis Charalampous, MSc,¹⁶ Vijay Kumar Chattu, MD,^{92,93} Simiao Chen, DSc,⁶⁰ Prof Rajiv Chowdhury, PhD,^{94,95} Prof Hanne Christensen, DMSci,⁹⁶ Sheng-Chia Chung, PhD,^{97,98} Joao Conde, PhD,⁹⁹ Barbara Corso, PhD,¹⁰⁰ Prof Natália Cruz-Martins, PhD,^{101,102} Giovanni Damiani, MD,^{103,104} Alejandro de la Torre-Luque, PhD,¹⁰⁵ Andreas K Demetriades, MD,^{106,107} Nikolaos Dervenis, MD,^{108,109} Mostafa Dianatinasab, MSc,^{110,111} Prof Diana Dias da Silva, PhD,^{112,69} Abdel Douiri, PhD,¹¹³ Prof David Edvardsson, PhD,^{114,115} Luchuo Engelbert Bain, PhD,¹¹⁶ Francesco Esposito, MD,¹¹⁷ Adeniyi Francis Fagbamigbe, PhD,^{118,119} Carla Sofia e Sá Farinha, MSc,^{120,121} Seyed-Mohammad Fereshtehnejad, PhD,^{49,122} João C Fernandes, PhD,¹²³ Pietro Ferrara, MD,¹²⁴ Peter Andras Gaal, PhD,^{125,126} Silvano Gallus, DSc,¹²⁷ Lucia Galluzzo, MA,⁴⁸ Mariana Gaspar Fonseca, PhD,¹²⁸ Prof Gus Gazzard, MD,^{129,130} Alessandro Gialluisi, PhD,¹³¹ Simona Giampaoli, MD,¹³² Prof Paramjit Singh Gill, DM,¹³³ James C Glasbey, MSc,¹³⁴ Giuseppe Gorini, MD,¹³⁵ Prof Michal Grivna, PhD,^{136,137} Abdul Hafiz, PhD,^{138,139} Josep Maria Haro, MD,^{140,141} Prof Jan Hartvigsen, PhD,^{142,143} Prof Simon I Hay, FMedSci,^{144,145} Behzad Heibati, PhD,¹⁴⁶ David Hillus, MD,¹⁴⁷ Mehdi Hosseinzadeh, PhD,^{148,149} Mihaela Hostiuc, PhD,¹⁵⁰ Sorin Hostiuc, PhD,^{151,152} Salman Hussain, PhD,^{153,154} Prof Gaetano Isola, PhD,¹⁵⁵ Olatunji Johnson, PhD,¹⁵⁶ Prof Jost B Jonas, MD,^{157,158} Tamas Joo, PhD,^{125,159} Jacek Jerzy Jozwiak, PhD,¹⁶⁰ Mikk Jürisson, PhD,¹⁶¹ Marina Karanikolos, PhD,^{162,163} Joonas H Kauppila, MD,^{164,165} Moien AB Khan, MSc,^{166,167} Khaled Khatab, PhD,^{168,16} Miloslav Klugar, PhD,^{153,170} Ai Koyanagi, MD,^{171,172} Om P Kurmi, PhD,^{173,174} Dian Kusuma, DSc, ^{175,176} Prof Carlo La Vecchia, MD, ¹⁷⁷ Ben Lacey, PhD, ^{70,178} Demetris Lamnisos, PhD,¹⁷⁹ Prof Heidi Jane Larson, PhD,^{180,144} Prof Anders O Larsson, PhD,^{181,182} Savita Lasrado, MS,¹⁸³ Paolo Lauriola, MD,¹⁸⁴ Prof Jeffrey V Lazarus, PhD,¹⁸⁵ Caterina Ledda, PhD,¹⁸⁶ Paul H Lee, PhD,¹⁸⁷ Mall Leinsalu, PhD,^{188,189} Matilde Leonardi, MD,¹⁹⁰ Miriam Levi, PhD,^{191,192} An Li, PhD,^{193,194} Christine Linehan, PhD,¹⁹⁵ Prof Giancarlo Logroscino, PhD,^{196,197} Prof Stefan Lorkowski, PhD, ^{198,199} Joana A Loureiro, PhD, ^{200,201} Prof Ronan A Lyons, MD, ²⁰² Áurea M Madureira-Carvalho, PhD, 112,203 Prof Azeem Majeed, MD, 204 Alexander G Mathioudakis, PhD,^{205,206} Colm McAlinden, PhD,²⁰⁷ Prof John J McGrath, MD,^{208,209} Prof Ritesh G Menezes, MD,²¹⁰ Alexios-Fotios A Mentis, MD,² Atte Meretoja, MD,^{212,213} Tuomo J Meretoja, MD,^{214,215} Tomislav Mestrovic, PhD,^{216,144} Junmei Miao Jonasson, PhD,²¹⁷ Bartosz Miazgowski, MD,^{218,21} Prof Tomasz Miazgowski, MD,²²⁰ Andreea Mirica, PhD,⁴¹ Shafiu Mohammed, PhD,^{221,82} Ali H Mokdad, PhD,^{144,145} Prof Ute Mons, PhD,²²² Joana Morgadoda-Costa, MSc,²²³ Francesk Mulita, PhD,^{224,225} Prof Christopher J L Murray, DPhil,^{144,145} Ionut Negoi, PhD,^{226,227} Ruxandra Irina Negoi, PhD,^{228,229} Serban Mircea Negru, MD,²³⁰ Evangelia Nena, MD,²³¹ Nurulamin M Noor, MRCP,^{232,233} Mircea Negru, MD,²³⁴ Evangelia Nena, MD,²⁴⁵ Nurulamin Mi Noor, MiC,²³⁶ George Ntaios, PhD,²³⁴ Prof Bogdan Oancea, PhD,²³⁵ Frank B Osei, PhD,²³⁶ Adrian Otoiu, PhD,⁴¹ Raffaele Palladino, MD,^{238,204} Songhomitra Panda-Jonas, MD,²³⁹ Prof Shahina Pardhan, PhD,²⁴⁰ Jay Patel, NA,^{241,242} Prof Mihaela Paun, PhD,^{243,244} Paolo Pedersini, MSc,²⁴⁵ Umberto Pensato, MD,²⁴⁶ Renato B Pereira, PhD,²⁴⁷ Prof Jorge Pérez-Gómez, PhD,²⁴⁸ Norberto Perico, MD,²⁴⁹ Ionela-Roxana Petcu, PhD,⁴¹ Carrie B Peterson, PhD,²⁵⁰ Marina Pinheiro, PhD,²⁴⁷ Prof Maarten J Postma, PhD,^{251,252} Alberto Raggi, PhD,¹⁹⁰ Amir Masoud Rahmani, PhD,²⁵ Chythra R Rao, MD,²⁵⁴ Prof Salman Rawaf, MD,^{204,255} Reza Rawassizadeh, PhD,²⁵⁶ Prof Giuseppe Remuzzi, MD,²⁴⁹ Abanoub Riad, DDS,^{257,153} Prof Simona Sacco, MD,²⁵⁸ Prof Mohammad Reza Saeb, PhD,²⁵⁹ Brijesh Sathian, PhD,^{260,261} Davide Sattin, PsyD,²⁶² Prof Nikolaos Scarmeas, PhD,^{263,264} Prof Falk Schwendicke, PhD,²⁶⁵ Rahman Shiri, PhD,²⁶⁶ Velizar Shivarov, PhD,^{267,268} Kibrom T Sibhatu, PhD,²⁶⁹ Prof Biagio Simonetti, PhD,^{270,271} Prof Søren T Skou, PhD,^{142,272} Prof Joan B Soriano, MD,^{273,274} Ireneous N Soyiri, PhD,²⁷⁵ Prof Nicholas Steel, PhD,^{276,277} Simona Cătălina Ștefan, PhD,²⁷⁸ Fridolin Steinbeis, MD,¹⁴⁷ Paschalis Steiropoulos, MD,²³¹ Leo Stockfelt, PhD,²⁷⁹ Prof Saverio Stranges, MD,^{280,28} Prof Johan Sundström, PhD,^{181,282} Prof Rafael Tabarés-Seisdedos, PhD,^{283,284} Arulmani Thiyagarajan, MPH,²⁸⁵ Roman Topor-Madry, PhD,^{286,287} Marcos Roberto Tovani-Palone, PhD,^{288,289} Nikolaos Tsilimparis, PhD,²⁹⁰ Brigid Unim, PhD,⁴⁸ Marco Vacante, PhD,⁷¹ Jef Van den Eynde, BSc,²⁹¹ Prof Tommi Juhani Vasankari, MD,^{292,293} Prof Massimiliano Veroux, PhD,²⁹⁴ Jorge Hugo Villafañe, PhD,²⁴⁵ Prof Francesco S Violante, MD,^{295,296} Yanzhong Wang, PhD,¹¹³ Ronny Westerman, DSc,²⁹⁷ Prof Charles D A Wolfe, MD,^{113,298} Grant M A Wyper, MSc,²⁹⁹ Prof Sanni Yaya, PhD,^{300,301} Prof Vesna Zadnik, PhD,³⁰² Jean-David Zeitoun, PhD,^{303,304} Prof Alimuddin Zumla, PhD, 305,306 Alberto Freitas, PhD, 307,1 Prof. Brecht Devleesschauwer, PhD.308,309

Affiliations

¹CINTESIS@RISE, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal; ²Public Health Unit, ULS Santo António, Porto, Portugal; ³National School of Public Health, Institute of Health Carlos III, Madrid, Spain; ⁴Scientific-Tools.Org, Bergamo, Italy; ⁵Research Department, RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania; ⁶Department of Public Health, Babes-Bolyai University, Cluj-Napoca, Romania; ⁷Department for Exposure Assessment and Environmental Health Indicators, German Environment Agency, Dessau-Roßlau, Germany; ⁸Department of Healthcare, University of Vlora, Vlora, Albania; ⁹Clinic of Social and Family Medicine, University of Crete, Heraklion, Greece; ¹⁰Independent researcher; ¹¹Institute of Gerontological Health Services and Nursing Research, Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany; ¹²Department of Disease Burden, Norwegian Institute of Public Health, Bergen, Norway; ¹³ Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon; ¹⁴National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; ¹⁵The Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University,

Boston, MA, USA; ¹⁶Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands; ¹⁷Department of Health Economics and Social Security, Jagiellonian University Medical College, Krakow, Poland; ¹⁸Clinical Epidemiology and Public Health Research Unit, Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; ¹⁹Research group for Childhood Cancer, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark; ²⁰Department of Health and Society, Faculty of Medicine, University of Applied and Environmental Sciences, Bogota, Colombia; ²¹Department of International Health, Maastricht University, Maastricht, Netherlands; ²²Department of Non-communicable Diseases and Injuries, Santé Publique France (Public Health France), Saint-Maurice, France; ²³Department of Medicine, University College Cork, Cork, Ireland; ²⁴Department of Geriatric Medicine, Mercy University Hospital, Cork, Ireland; ²⁵Anatomy Department, University of Malta, Msida, Malta; ²⁶Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina University, Messina, Italy; ²⁷School of Public Health, University College Cork, Cork, Ireland; ²⁸Department of Juridical and Economic Studies, La Sapienza University, Rome, Italy; ²⁹Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran; ³⁰Department of Biosciences and Nutrition, Karolinska University Hospital, Huddinge, Sweden; ³¹Department of Obstetrics & Gynecology, University of Texas, Galveston, TX, USA; ³²School of Public Health, Imperial College London, London, UK; ³³School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ³⁴School of Computing, Mathematics and Engineering, Charles Sturt University, Wagga Wagga, NSW, Australia; ³⁵Information and Communication Sciences and Technologies Pole, Mathematics, Algorithms and Decision Team, ENSTA Bretagne, Brest, France; ³⁶Bordeaux School of Public Health, University of Bordeaux, Bordeaux, France; ³⁷Research Program of Epidemiology and Public Health, Pompeu Fabra University, Barcelona, Spain; ³⁸Department of Experimental and Health Sciences, Biomedical Research Networking Center in Epidemiology and Public Health (CiberESP), Madrid, Spain; ³⁹Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁴⁰Cardiology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁴¹Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania; ⁴²Department of Medicine, University of Thessaly, Volos, Greece; ⁴³Non-Communicable Diseases & Environment Programme, Barcelona Institute for Global Health, Barcelona, Spain; ⁴⁴Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain; ⁴⁵Department of Sociology and Social Work, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; ⁴⁶Center for International Health, Ludwig Maximilians University, Munich, Germany; ⁴⁷Department of Public Health, Birmingham City University, Birmingham, UK; ⁴⁸Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, National Institute of Health, Rome, Italy; ⁴⁹Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden; ⁵⁰School of Health and Social Studies, Dalarna University, Falun, Sweden; ⁵¹Department of Physiotherapy, University of Sharjah, Sharjah, United Arab Emirates; ⁵²Department Community Medicine and Rehabilitation, Umeå University, Umea, Sweden; ⁵³Oral and Maxillofacial Surgery, Justus Liebig University of Giessen, Giessen, Germany; ⁵⁴Northumbria HealthCare NHS Foundation Trust, National Health Service (NHS) Scotland, Newcastle upon Tyne, UK; 55 School of Business, University of Leicester, Leicester, UK; ⁵⁶Department of Psychiatry, Autonomous University of Madrid (Universidad Autónoma de Madrid), Madrid, Spain; ⁵⁷CIBERSAM, Institute of Health Carlos III, Madrid, Spain; ⁵⁸Department of Hypertension, Medical University of Lodz, Lodz, Poland; ⁵⁹Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland; ⁶⁰Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany; ⁶¹T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; ⁶²Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; ⁶³Heidelberg Institute of Global Health (HIGH), Heidelberg University Hospital, Heidelberg, Germany; ⁶⁴Center for Primary Care, Harvard University, Boston, MA, USA; ⁶⁵Department of Psychiatry, University of Münster, Münster, Germany; ⁶⁶Department of Psychiatry, Melbourne Medical School, Melbourne, VIC, Australia; ⁶⁷Department of Mental Health, AUSL Romagna, Ravenna, Italy; ⁶⁸Biological Sciences Department, University of Porto, Porto, Portugal; ⁶⁹Research Unit on Applied Molecular Biosciences (UCIBIO), University of Porto, Porto, Portugal; ⁷⁰Nuffield Department of Population Health, University of Oxford, Oxford, UK; ⁷¹Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy; ⁷²Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences, Zanjan, Iran;

⁷³Department of Research and Innovation, Petanux Research GmBH, Bonn, Germany; ⁷⁴School of Medicine and University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁷⁵Division of Country Health Policies and Systems, World Health Organization (WHO), Denmark, Denmark; ⁷⁶University of Genoa, Genoa, Italy; ⁷⁷Ophthalmology Department, Moorfields Eye Hospital NHS Foundation Trust, London, UK; ⁷⁸International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK; ⁷⁹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; ⁸⁰Department of Woman and Child Health and Public Health, Agostino Gemelli University Polyclinic IRCCS (Fondazione Policlinico Universitario A. Gemelli IRCCS), Roma, Italy; ⁸¹Global Health Research Institute, Università Cattolica del Sacro Cuore (Catholic University of Sacred Heart), Roma, Italy; ⁸²Department of Health Care Management, Technical University of Berlin, Berlin, Germany; ⁸³Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Romania, Craiova, Romania; ⁸⁴Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy; ⁸⁵Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal; ⁸⁶Department of Medicine, University of Udine, Udine, Italy; ⁸⁷Department of Mental Health, Healthcare Agency "Friuli Occidentale", Pordenone, Italy; ⁸⁸Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; ⁸⁹MultiMedica, IRCCS, Sesto S. Giovanni, Italy; ⁹⁰Department of Public Health and Infectious Diseases, La Sapienza University, Rome, Italy; ⁹¹Institute of Applied Health Research, University of Birmingham, Birmingham, UK; ⁹²Faculty of Medical Sciences, University of the West Indies, St Augustine, Trinidad and Tobago; ⁹³Independent Consultant, Athens, Greece; ⁹⁴Florida International University, Florida International University, Miami, FL, USA; ⁹⁵Department of Epidemiology, University of Bern, Bern, Switzerland; ⁹⁶Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; ⁹⁷Department of Health Informatics, University College London, London, UK; ⁹⁸Health Data Research UK, London, UK; ⁹⁹Nova Medical School, Nova University of Lisbon, Lisbon, Portugal; ¹⁰⁰Institute of Neuroscience, National Research Council, Pisa, Italy; ¹⁰¹Therapeutic and Diagnostic Technologies, Cooperativa de Ensino Superior Politécnico e Universitário (Polytechnic and University Higher Education Cooperative), Gandra, Portugal; ¹⁰²Institute for Research and Innovation in Health, University of Porto, Porto, Portugal; ¹⁰³IRCCS Istituto Ortopedico Galeazzi (Galeazzi Orthopedic Institute IRCCS), University of Milan, Milan, Italy; ¹⁰⁴Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA; ¹⁰⁵Department of Legal Medicine, Psychiatry and Pathology, Complutense University of Madrid (Universidad Complutense de Madrid), Madrid, Spain; ¹⁰⁶Department of Neurosurgery, University of Edinburgh, Edinburgh, UK; ¹⁰⁷Department of Neurosurgery, National Health Service (NHS) Scotland, Edinburgh, UK; ¹⁰⁸St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK; ¹⁰⁹Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; ¹¹⁰Department of Epidemiology, Maastricht University, Maastricht, Netherlands; ¹¹¹Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran; ¹¹²Toxicology Research Unit (TOXRUN), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU) (University Polytechnic Higher Education Cooperative), Gandra, Portugal; ¹¹³School of Population Health and Environmental Sciences, King's College London, London, UK; ¹¹⁴School of Nursing and Midwifery, La Trobe University, Melbourne, VIC, Australia; ¹¹⁵Department of Nursing, Umeå University, Umea, Sweden; ¹¹⁶Lincoln International Institute for Rural Health, University of Lincoln, Lincoln, UK; ¹¹⁷Dipartimento di Scienze Biomediche e Neuromotorie (Department of Biomedical and Neuromotor Sciences), University of Bologna, Bologna, Italy; ¹¹⁸Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria; ¹¹⁹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; ¹²⁰Dissemination Division, National Institute of Statistics, Lisbon, Portugal; ¹²¹Activity Planning and Control Unit, Directorate-General of Health (DGS), Lisbon, Portugal; ¹²²Division of Neurology, University of Ottawa, Ottawa, ON, Canada; ¹²³Center for Biotechnology and Fine Chemistry, Catholic University of Portugal, Porto, Portugal; ¹²⁴Research Center on Public Health, University of Milan Bicocca, Monza, Italy; ¹²⁵Health Services Management Training Centre, Semmelweis University, Budapest, Hungary; ¹²⁶Department of Applied Social Sciences, Sapientia Hungarian University of Transylvania, Târgu-Mures, Romania; ¹²⁷Department of Environmental Health Sciences, Mario Negri Institute for Pharmacological Research, Milan, Italy; ¹²⁸National Health Service, London, UK; ¹²⁹Institute of Ophthalmology, University College London, London, UK; ¹³⁰Moorfields Eye Hospital NHS Foundation Trust, London, UK; ¹³¹Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy; ¹³²Department of Cardiovascular Endocrine-metabolic Diseases and Aging, Istituto

Superiore di Sanità, Rome, Italy; ¹³³Warwick Medical School, University of Warwick, Coventry, UK; ¹³⁴NIHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK; ¹³⁵Oncological Network, Prevention and Research Institute, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy; ¹³⁶College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates; ¹³⁷Department of Public Health and Preventive Medicine, Charles University, Prague, Czech Republic, ¹³⁸College of Medicine, Umm AL Qura University, Makkah, Saudi Arabia; ¹³⁹MSc Epidemiology Programme, London School of Hygiene & Tropical Medicine, London, UK; ¹⁴⁰Research Unit, University of Barcelona, Barcelona, Spain; ¹⁴¹Biomedical Research Networking Center for Mental Health Network (CiberSAM), Barcelona, Spain; ¹⁴²Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; ¹⁴³Research Department, Nordic Institute of Chiropractic and Clinical Biomechanics, Odense, Denmark; ¹⁴⁴Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; ¹⁴⁵Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA; ¹⁴⁶Research Unit of Population Health, University of Oulu, Oulu, Finland; ¹⁴⁷Department of Infectious Diseases and Respiratory Medicine, Charité Medical University Berlin, Berlin, Germany; 148 Institute of Research and Development, Duy Tan University, Da Nang, Viet Nam; ¹⁴⁹Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq; ¹⁵⁰Internal Medicine Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ¹⁵¹Department of Legal Medicine and Bioethics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ¹⁵²Clinical Legal Medicine Department, National Institute of Legal Medicine Mina Minovici, Bucharest, Romania, ¹⁵³Czech National Centre for Evidence-based Healthcare and Knowledge Translation, Masaryk University, Brno, Czech Republic; ¹⁵⁴Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; ¹⁵⁵Department of General Surgery and Surgical-Medical Specialties, University of Catania, Catania, Italy; ¹⁵⁶Department of Mathematics, University of Manchester, Manchester, UK; ¹⁵⁷Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland; ¹⁵⁸Department of Ophthalmology, Heidelberg University, Mannheim, Germany; ¹⁵⁹Hungarian Health Management Association, Budapest, Hungary; ¹⁶⁰Department of Family Medicine and Public Health, University of Opole, Opole, Poland, ¹⁶¹Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia; ¹⁶²European Observatory on Health Systems and Policies, London School of Hygiene & Tropical Medicine, London, UK; ¹⁶³Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; ¹⁶⁴Surgery Research Unit, University of Oulu, Oulu, Finland; ¹⁶⁵Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; ¹⁶⁶Family Medicine Department, United Arab Emirates University, Al Ain, United Arab Emirates; ¹⁶⁷Primary Care Department, NHS North West London, London, UK; ¹⁶⁸Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK; ¹⁶⁹College of Arts and Sciences, Ohio University, Zanesville, OH, USA; ¹⁷⁰Institute for Health Information and Statistics of the Czech Republic, Prague, Czech Republic; ¹⁷¹Biomedical Research Networking Center for Mental Health Network (CIBERSAM), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; ¹⁷²Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; ¹⁷³Faculty of Health and Life Sciences, Coventry University, Coventry, UK; ¹⁷⁴Department of Medicine, McMaster University, Hamilton, ON, Canada; ¹⁷⁵Department of Health Services Research and Management, City University of London, London, UK; ¹⁷⁶Faculty of Public Health, University of Indonesia, Depok, Indonesia; ¹⁷⁷Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; ¹⁷⁸National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK; ¹⁷⁹Department of Health Sciences, European University Cyprus, Nicosia, Cyprus; ¹⁸⁰Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; ¹⁸¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ¹⁸²Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, Uppsala, Sweden; ¹⁸³Department of Otorhinolaryngology, Father Muller Medical College, Mangalore, India; ¹⁸⁴International Society Doctors for the Environment, Arezzo, Italy; ¹⁸⁵Barcelona Institute for Global Health, Barcelona, Spain; ⁸⁶Clinical and Experimental Medicine, University of Catania, Catania, Italy; ¹⁸⁷Department of Health Sciences, University of Leicester, Leicester, UK; ¹⁸⁸School of Social Sciences, Södertörn University, Huddinge, Sweden; ¹⁸⁹Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia; ¹⁹⁰UO Neurologia, Salute Pubblica e Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta (Neurology, Public Health

and Disability Unit, Carlo Besta Neurological Institute), Milan, Italy; ¹⁹¹Department of Prevention, USL Tuscany Center, Firenze, Italy; ¹⁹²Department of Health Sciences, University of Florence, Florence, Italy; ¹⁹³Center for Dentistry and Oral Hygiene, University of Groningen, Groningen, Netherlands; ¹⁹⁴Stomatological Hospital, Southern Medical University, Guangzhou, China; ¹⁹⁵UCD Centre for Disability Studies, University College Dublin, Dublin, Ireland; ¹⁹⁶Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy; ¹⁹⁷Department of Clinical Research in Neurology, Fondazione Cardinale Giovanni Panico Hospital, Tricase, Italy; ¹⁹⁸Institute of Nutritional Sciences, Friedrich Schiller University Jena, Jena, Germany; ¹⁹⁹Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena, Germany; ²⁰⁰Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), University of Porto, Porto, Portugal; ²⁰¹School of Health, Polytechnic Institute of Porto, Portugal; ²⁰²School of Medicine, Swansea University, Swansea, UK; ²⁰³Laboratório de Farmacognosia (LAQV) (Associated Laboratory for Green Chemistry, University of Porto, Porto, Portugal; ²⁰⁴Department of Primary Care and Public Health, Imperial College London, London, UK; ²⁰⁵Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; ²⁰⁶North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK; ²⁰⁷Department of Ophthalmology, Singleton Hospital, Swansea, UK; ²⁰⁸Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia; ²⁰⁹National Centre for Register-based Research, Aarhus University, Aarhus, Denmark; ²¹⁰Forensic Medicine Division, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; ²¹¹International Dx Department, BGI Genomics, Copenhagen, Denmark; ²¹²Neurology Unit, Helsinki University Hospital, Helsinki, Finland; ²¹³School of Health Sciences, University of Melbourne, Melbourne, VIC, Australia; ²¹⁴Breast Surgery Unit, Helsinki University Hospital, Helsinki, Finland; ²¹⁵University of Helsinki, Helsinki, Finland; ²¹⁶University Centre Varazdin, University North, Varazdin, Croatia; ²¹⁷School of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden; ²¹⁸Center for Innovation in Medical Education, Pomeranian Medical University, Szczecin, Poland; ²¹⁹Pomeranian Medical University, Szczecin, Poland; ²²⁰Department of Propedeutics of Internal Diseases & Arterial Hypertension, Pomeranian Medical University, Szczecin, Poland; ²²¹Health Systems and Policy Research Unit, Ahmadu Bello University, Zaria, Nigeria; 222 Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; ²²³University Hospital Center of Porto, University of Porto, Porto, Portugal; ²²⁴Department of Surgery, General University Hospital of Patras, Patras, Greece; ²²⁵Medical School, University of Thessaly, Larissa, Greece; ²²⁶Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ²²⁷Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania; ²²⁸Department of Anatomy and Embryology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 229 Department of Cardiology, Cardio-Aid, Bucharest, Romania; ²³⁰Department of Oncology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania;²³¹Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece; ²³²Medical Research Council Clinical Trials Unit, University College London, London, UK; ²³³Department of Gastroenterology, Cambridge University Hospitals, Cambridge, UK; ²³⁴Department of Internal Medicine, University of Thessaly, Larissa, Greece; ²³⁵Department of Applied Economics and Quantitative Analysis, University of Bucharest, Bucharest, Romania; ²³⁶Faculty of Geo-Information Science and Earth Observation, University of Twente, Enschede, Netherlands; ²³⁷Department of Mathematics and Statistics, University of Energy and Natural Resources, Sunyani, Ghana; ²³⁸Department of Public Health, University of Naples Federico II, Naples, Italy; ²³⁹Privatpraxis, Heidelberg, Germany; ²⁴⁰Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK; ²⁴¹Global Health Governance Programme, University of Edinburgh, Edinburgh, UK; ²⁴²School of Dentistry, University of Leeds, Leeds, UK; ²⁴³Department of Bioinformatics and Biostatistics, National Institute of Research and Development for Biological Sciences, Bucharest, Romania; ²⁴⁴Department of Statistics and Cybernetics, University of Bucharest, Bucharest, Romania; ²⁴⁵Clinical Research Department, IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy; ²⁴⁶Department of Neurology, IRCCS Humanitas Research Hospital, Milan, Italy; ²⁴⁷Department of Chemistry, University of Porto, Porto, Portugal; ²⁴⁸Departamento de Didáctica de la Expresión Musical, Plástica y Corportal, University of Extremadura, Cáceres, Spain; ²⁴⁹Mario Negri Institute for Pharmacological Research, Bergamo, Italy; ²⁵⁰Independent Consultant, Copenhagen, Denmark; ²⁵¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ²⁵²Center of Excellence in

Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran (Padjadjaran University), Bandung, Indonesia; ²⁵³Future Technology Research Center, National Yunlin University of Science and Technology, Yunlin, Taiwan; ²⁵⁴Department of Community Medicine, Manipal Academy of Higher Education, Manipal, India; ²⁵⁵Ácademic Public Health England, Public Health England, London, UK; ²⁵⁶Department of Computer Science, Boston University, Boston, MA, USA; ²⁵⁷Department of Public Health, Masaryk University, Brno, Czech Republic; ²⁵⁸Department of Neurology, University of L'Aquila, L'Aquila, Italy; ²⁵⁹Department of Polymer Technology, Independent Consultant, Gdansk, Poland; ²⁶⁰Geriatric and Long Term Care Department, Hamad Medical Corporation, Doha, Qatar; ²⁶¹Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, UK; ²⁶²IRCCS Istituti Clinici Scientifici Maugeri (IRCCS Maugeri Scientific Clinical Institute), Milan, Italy; ²⁶³Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece; ²⁶⁴Department of Neurology, Columbia University, New York, NY, USA; ²⁶⁵Oral Diagnosis, Digital Health and Health Services Research, Charité University Medical Center Berlin, Berlin, Germany; ²⁶⁶Finnish Institute of Occupational Health, Helsinki, Finland; ²⁶⁷Clinical Immunology and Hematology, Sofiamed University Hospital, Sofia, Bulgaria; ²⁶⁸Department of Genetics, Sofia University "St. Kliment Ohridiski", Sofia, Bulgaria; ²⁶⁹Department of Agricultural Economics and Rural Development, University of Göttingen, Göttingen, Germany; ⁰Department of Law, Economics, Management and Quantitative Methods, University of Sannio, Benevento, Italy; ²⁷¹WSB University in Gdańsk, Gdańsk, Poland; ²⁷²Department of Physiotherapy and Occupational Therapy, Næstved-Slagelse-Ringsted Hospitals, Slagelse, Denmark; 273 Hospital Universitario de La Princesa (Princess University Hospital), Autonomous University of Madrid, Madrid, Spain;²⁷⁴Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES) (Center for Biomedical Research in Respiratory Diseases Network), Madrid, Spain; ²⁷⁵Hull York Medical School, University of Hull, Hull City, UK; ²⁷⁶Department of Primary Care and Public Health, University of East Anglia, Norwich, UK; 277 Public Health England, London, UK; ²⁷⁸Management Department, Bucharest University of Economic Studies, Bucharest, Romania; ²⁷⁹Occupational and Environmental Medicine Department, University of Gothenburg, Gothenburg, Sweden; ²⁸⁰Department of Epidemiology & Biostatistics, The University of Western Ontario, London, ON, Canada; ²⁸¹Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg; ²⁸²The George Institute for Global Health, Sydney, NSW, Australia; ²⁸³Department of Medicine, University of Valencia, Valencia, Spain; ²⁸⁴Institute of Health Carlos III, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain; ²⁸⁵Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology, Bremen, Germany; ²⁸⁶Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland; 287 Agency for Health Technology Assessment and Tariff System, Warsaw, Poland, 288 Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India; ²⁸⁹Modestum LTD, Eastbourne, UK; ²⁹⁰Department of Vascular Surgery, Ludwig Maximilians University, Munich, Germany; ²⁹¹Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium; ²⁹²UKK Institute, Tampere, Finland; ²⁹³Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ²⁹⁴Department of Medical and Surgical Sciences and Advanced Technologies, University of Catania, Catania, Italy; ²⁹⁵Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; ²⁹⁶Occupational Health Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy; ²⁹⁷Competence Center of Mortality-Follow-Up of the German National Cohort, Federal Institute for Population Research, Wiesbaden, Germany; ²⁹⁸NIHR-Biomedical Research Centre (NIHR-BRC), Guy's and St. Thomas' Hospital and Kings College London, London, UK; ²⁹⁹School of Health and Wellbeing, University of Glasgow, Glasgow, UK; ³⁰⁰School of International Development and Global Studies, University of Ottawa, Ottawa, ON, Canada; ³⁰¹The George Institute for Global Health, Imperial College London, London, UK; ³⁰²Epidemiology and Cancer Registry Sector, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ³⁰³Centre of Clinical Epidemiology, Hôtel Dieu Hospital, Assistance Publique Hôpitaux de Paris (Public Hospitals of Paris), Paris, France; ³⁰⁴Gastroenterology and Nutrition, Saint-Antoine Hospital, Assistance Publique Hôpitaux de Paris (Public Hospitals of Paris), Paris, France; ³⁰⁵Department of Infection, University College London, London, UK; ³⁰⁶NIHR-Biomedical Research Centre (NIHR-BRC), University College London Hospitals, London, UK; ³⁰⁷Department of Community Medicine, Information and Health Decision Sciences, University of Porto, Porto, Portugal; ³⁰⁸Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium;

³⁰⁹Department of Translational Physiology, Infectiology and Public Health, Ghent University, Ghent, Belgium.

Involvement of humans in the study

Only secondary data was used for this study.

Authors' contributions

JVS, APM, BB, DAG, DP, EAM, FG, FF, GS, CHN, IN, JLP, JAH, KK, LM, NG, RS, RH, RH, RO, SC, SM, ZK, AF and BD have conceived and designed the study and drafted the work. JVS, FG and RH performed the data analysis. Contributions for additional authors may be found in the appendix. All authors have given inputs on the interpretation of data, substantially revised the manuscript and have approved the submitted version.

Funding

T W Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. L Belo acknowledges the support from FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. D A Bennett is supported by the UK Medical Research Council Population Health Research Unit at the University of Oxford. M Carvalho acknowledges the support from FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. A L Catapano is supported in part by the Ministero della Salute ricerca corrente. J S Chandan acknowledges the National Institute of Health Research. J Conde would like to acknowledge the European Research Council Starting Grant (ERC-StG-2019-848325). D Dias da Silva acknowledges the projects UIDP/04378/2022 and UIDB/04378/2022 of the Research Unit on Applied Molecular Biosciences UCIBIO; the project LA/P/ 0140/2022 of the Associate Laboratory Institute for Health and Bioeconomy i4HB; and IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies (project PsiloPharm) and TOXRUN Toxicology Research Unit, University Institute of Health Sciences, IUCS-CESPU, Portugal. A Douiri acknowledges support by King's Health Partners/Guy's and St Thomas Charity "MLTC Challenge Fund" (grant number EIC180702) and the NIHR Applied Research Collaboration (ARC) South London at King's College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. J C Fernandes acknowledges support from Fundação para a Ciência e Tecnologia (FCT) with funding for UID/Multi/50016/2019. G Gazzard acknowledges support from NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK and Institute of Ophthalmology, University College London, UK. P S Gill acknowledges being NIHR senior investigator for the NIHR Department of Health and Social Care. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. J C Glasbey is supported by a UK National Institute of Health Research Doctoral Research Fellowship (NIHR300175). S Hussain was supported from Operational Programme Research, Development and Education "Project, Postdoc2MUNI" (No.CZ.02.2.6 9/0.0/0.0/18_053/0016952). M AB Khan acknowledges support as recipient of research grants G00003634- CMHS "NP-22-20 80, 000 AED (2021), G00003569 NP-21-13 80,000 AED, and 1976—SDG Research Program Grant 40,000 AED. B Lacey acknowledges support from UK Biobank, which is funded largely by the UK Medical Research Council and Wellcome. J A Loureiro was supported by National Funds through Fundação para a Ciência e Tecnologia (FCT) under the Scientific Employment Stimulus' Institutional Call-[CEECINST/00049/2018]. S Lorkowski acknowledges institutional support from the Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig (Germany; German Federal Ministry of Education and Research; grant agreement number 01EA1808A). A G Mathioudakis acknowledges support by the National Institute for Health and Care Research Manchester Biomedical Research Centre (NIHR Manchester BRC) and by an NIHR Clinical Lectureship in Respiratory Medicine. J J McGrath was supported by the Danish National Research Foundation (Niels Bohr Professorship) and is employed by The Queensland Centre for Mental Health Research, which receives core funding from the Queensland Health. S Mohammed reports fellowship grant from Alexander von Humboldt Foundation, outside the submitted work. L Monasta received support from the Italian Ministry of Health, through the contribution given to the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (RC 34/2017). P Pedersini was supported and funded by the Italian Ministry of Health-Ricerca Corrente 2021. M Pinheiro thanks FCT for funding

through program DL 57/2016 Norma transita. A Raggi acknowledges support by the Italian Ministry of Health (RRC). A Riad was supported by the project of the Ministry of Education, Youth and Sports of the Czech Republic (Systemic Risk Institute "SYRI": LX22NPO5101) and the projects of Masaryk University (MUNI/A/1402/2021 and MUNI/IGA/1104/2021). ST Skou is currently funded by a grant from Region Zealand (Exercise First) and two grants from the European Union's Horizon 2020 Research and Innovation Program, one from the European Research Council (MOBILIZE, grant agreement No 801790) and the other under grant agreement No 945377 (ESCAPE). J B Soriano is supported by Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias. Instituto de Salud Carlos III, Madrid, Spain. L Stockfelt was funded by the Swedish state under the agreement between the Swedish government and the country councils, the ALF-agreement. Johan Sundström acknowledges stock ownership in Anagram kommunikation AB and Symptoms Europe AB. R Tabares-Seisdedos is supported by the Spanish Ministry of Science and Innovation, Institute of Health Carlos III, CIBERSAM, INCLIVA (PID2021-129099OB-I00). M R Tovani-Palone acknowledges Saveetha Institute of Medical and Technical Sciences (SIMATS) for its support. J H Villafañe was supported and funded by the Italian Ministry of Health-Ricerca Corrente 2021. A Zumla acknowledges grant support from the Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Diseases Epidemics (PANDORA-ID-NET) ONE-HEALTH (Europe-Africa) consortium funded by the European and Developing Countries Clinical Trials Partnership, which is supported by Horizon 2020, the EU's Framework Programme for Research and Innovation.

Availability of data and materials

The datasets analysed during the current study are publicly available in the GBD 2019 Results Tool and GBD 2019 Compare repositories (https://vizhub. healthdata.org/gbd-results/ and https://vizhub.healthdata.org/gbd-compare, respectively).

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

J Alonso reports grants or contracts from Instituto de Salud Carlos III, Spain MINDCOVID. COV20/0711, Instituto de Salud Carlos III, Spain PROMES-U. PI20/00006, and Departament de Salut, Generalitat de Catalunya, Spain. WEMWBS-CAT, SA-2021-741, as payments to their institution, outside the submitted work. R Ancuceanu reports consulting fees from Abbvie; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbive, B Braun, Sandoz, and Laropharm; support for attending meetings and/or travel from Abbive; all outside the submitted work. J Ärnlöv payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca and Novartis; participation on Advisory Boards for AstraZeneca, Boehringer Ingelheim, and Astella; all outside the submitted work. TW Bärnighausen reports research grants from the European Union (Horizon 2020 and EIT Health), German Research Foundation (DFG), US National Institutes of Health, German Ministry of Education and Research, Alexander von Humboldt Foundation, Else-Kröner-Fresenius-Foundation, Wellcome Trust, Bill & Melinda Gates Foundation, KfW, UNAIDS, and the WHO; consulting fees for KfW on the OSCAR initiative in Vietnam; participation on a Data Safety Monitoring Board or Advisory Board with NIH-funded study "Healthy Options" (PIs: Smith Fawzi, Kaaya), Chair, Data Safety and Monitoring Board (DSMB), German National Committee on the "Future of Public Health Research and Education", Chair of the scientific advisory board to the EDCTP Evaluation, Member of the UNAIDS Evaluation Expert Advisory Committee, National Institutes of Health Study Section Member on Population and Public Health Approaches to HIV/AIDS (PPAH), US National Academies of Sciences, Engineering, and Medicine's Committee for the "Evaluation of Human Resources for Health in the Republic of Rwanda under the President's Emergency Plan for AIDS Relief (PEPFAR)", University of Pennsylvania (UPenn) Population Aging Research Center (PARC) External Advisory Board Member; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as Co-chair of the

Global Health Hub Germany (which was initiated by the German Ministry of Health). S Basu reports grants from the US National Institutes of Health and US Centers for Disease Control and Prevention; consulting fees from University of California San Francisco; patents planned, issued or pending, for a multi-modal patient outreach system; participation on an advisory board with La Scuola International School; leadership or fiduciary role on a board with Waymark, paid or unpaid; personal stock options in Collective Health and Waymark; all outside the submitted work. B Baune reports personal payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen Cilag and LivaNova, outside the submitted work. L Belo reports other financial or non-financial interests from the FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. B Bikbov reports grants or contracts from the European Commission as personal payments, and from the Lombardy Region as payments to their institution; support for attending a meeting from the European Commission; leadership or fiduciary role, unpaid, in the Advocacy Working Group at the International Society of Nephrology; all outside the submitted work. D Buonsenso reports grants from Pfizer and Roche on long covid; support for attending meetings and/or travel from Pfizer for the ESPID meeting on covid vaccines; participation on a Data Safety Monitoring Board or Advisory Board from Pfizer for pneumococcal vaccines; all outside the submitted work. R Busse reports grants or contracts from the Innovation Fund (by Federal Joint Committee) as payments to their institution; consulting fees from Dresden hospitals and Paracelsus hospitals as personal payments; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Lilly, Abbvie and the Barmer Sickness Fund as personal payments; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with the Government Commission on Hospital Reform: all outside the submitted work. M Carvalho reports other financial or non-financial interests from the FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. J S Chandan reports grants or contracts from the National Institute for Health Research through College of Policing, the Youth Endowment Fund at the University of Birmingham and the Home Office. H Christensen reports grants or contracts from Veluxfonden, Novofonden, Helsefonden, Lundbeck fonden, and Tværsfonden; royalites and licenses from Gyldendals forlag (Medicinsk Kompendium); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer and BMS; leadership or fiduciary role in the Action Plan for Stroke in Europe as Chair, (unpaid); all outside the submitted work. J Conde reports grants from the European Research Council Starting ERC-StG-2019-848325 (funding 1.5 M€) outside the submitted work. D Dias da Silva reports grants or contracts from faculty of Pharmacy of University of Porto as personal payment for lecturers and research activities, escola Superior de Saúde-Instituto Politécnico de Leiria as personal payment for lecturers, and Instituto Universitário de Ciências da Saúde (IUCS) as personal payment for lecturers; consulting fees from Albert Labs as personal payments and payments to their institution, Eurox Pharma as payments to their institution; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Faculty of Pharmacy of University of Porto, Escola Superior de Saúde—Instituto Politécnico de Leiria, and Instituto Universitário de Ciências da Saúde (IUCS) all as personal payments for lectures; support to attend ICT 2022 - XVIth International Congress of Toxicology from Eurox Pharma; leadership or fiduciary role in the Portuguese Association of Forensic Sciences (APCF) as a member of the board; receipt of support to buy materials to research from Albert Labs and Eurox Pharma; all outside the submitted work. G Gazzard reports consulting fees from Alcon, Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Ripple, Santen, Sight Sciences, Thea, Vialase, and Zeiss; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alcon, Allergan, Belkin, Glaukos, Ivantis, Lumibird, McKinsey, Reichert, Sight Sciences, and Thea; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with the President UK & Ireland Glaucoma Society, and as an Advisor for Glaucoma UK Charity; al outside the submitted work. N Ghith reports support for the present manuscript from Novo Nordisk Foundation (NNF16OC0021856) as a grant to the research group. P S Gill reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, as NIHR senior investigator for the NIHR Department of Health and Social Care, UK, outside the submitted work. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social

Care. R Hrzic reports support for the present manuscript from the Department of International Health, Care and Public Health Research Institute - CAPHRI, Maastricht University, Maastricht, the Netherlands. J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis and Adamed as personal fees, outside the submitted work. M AB Khan reports grants from G00003634- CMHS - NP-22-20 (80,000 AED), G00003569 NP-21-13 (80,000 AED), and 1976-SDG Research Program Grant (40,000 AED), outside the submitted work. M Klugar reports grants from Czech-Norwegian Collaboration on Meta-Research and Critical Thinking Education in Healthcare (EHP-CZ-ICP-2-009), Evidence Implementation in Clinical Practice (2020-1-DE01-KA203-005669), Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic (LTC20031), Strategic Partnership in Innovation and Development of Evidence-Based Healthcare (2019-1-CZ01-KA202-061350), all as payments to their institution; membership of Cochrane advisory board for Evidence Advocacy, unpaid; other non-financial interests as Director of Cochrane, JBI and GRADE centres of the Czech Republic; all outside the submitted work. H J Larson reports research grants to the London School of Hygiene and Tropical Medicine from the Janssen, Merck, and the MarcArthur Foundation; support for travel from Merrimon Honorary Lecture, UNC; all outside the submitted work. J V Lazarus reports grants AbbVie, Gilead Sciences, MSD, Roche Diagnostics as grants to ISGlobal; consulting fees from NovoVax; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Gilead Sciences, Intercept, Janssen, Novo Nordisk; unpaid participation on a Data Safety Monitoring Board or Advisory Board for a same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (The QuickStart Study): a cluster randomised control trial - Australia; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, as a Member of EASL Public Health and Policy Committee, co-chair of HIV Outcomes, and SHARE Global Health Foundation; all outside the submitted work. G Logroscino reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche Spa for a teaching course, outside the submitted work. S Lorkowski reports grants or contracts from Akcea Therapeutics Germany as payments made to their institution; consulting fees from Danone, Novartis Pharma, and Swedish Orphan Biovitrum (SOBI) as personal payments; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Akcea Therapeutics Germany, AMARIN Germany, Amedes Holding, AMGEN, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankvo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis Pharma, Novo Nordisk Pharma, Roche Pharma, Sanofi-Aventis, and SYNLAB Holding Deutschland & SYNLAB Akademie, all as personal payments; support for attending meetings and/or travel from AMGEN and NOVO Nordisk Pharma as personal payments; participation on a Data Safety Monitoring Board or Advisory Board with Akcea Therapeutics Germany, AMGEN, Daiichi Sankyo Deutschland, Novartis, and Sanofi-Aventis as personal payments; all outside the submitted work. A M Madureira-Carvalho reports grants or contracts from Instituto Universitário de Ciências da Saúde (IUCS) as personal payments; consulting fees from Albert lab as personal and institutional payments and from Eurox Pharma as institutional payments; payment for lectures from Instituto Universitário de Ciências da Saúde (IUCS); support from Eurox Pharma to attend ICT 2022 – XVIth International Congress of Toxicology; leadership or fiduciary role, paid or unpaid, as Board Treasurer for the Portuguese Association of Forensic Sciences (APCF); receipt of support to buy materials for research from Albert Labs and Eurox Pharma; all outside the submitted work. A-F Mentis reports grants or contracts from 'MilkSafe: A novel pipeline to enrich formula milk using omics technologies', a research co financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH—CRE-ATE—INNOVATE (project code: T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860) (both outside of the present manuscript); stock or stock options in a family winery; other financial or non-financial interest as a scientific officer with BGI Group; all outside the submitted work. S Mohammed reports support for the present manuscript from the Bill and Melinda Gates Foundation; a fellowship grant from the Alexander von Humboldt Foundation, outside the submitted work. A Otoiu reports grants or contracts from the Bucharest University for Economic Studies as personal payments, and from European Commission: Horizon 2020 as payments made to their institution; both outside the submitted work. R

Palladino reports grants or contracts from the UK MS Society; consulting fees from Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD; all outside the submitted work. C B Peterson reports grants or contracts from a consultancy with WHO Regional Office for Europe, focus on disability inclusion in health sectors as personal payments; consulting fees from the WHO Regional Office for Europe, outside the submitted work. M Pinheiro reports grants or contracts from Fundação para a Ciência e Tecnologia (FCT) (research grant) outside the submitted work. M J Postma reports stock or stock options Health-Ecore (Zeist, NL) and PAG BV (Groningen, NL), outside the submitted work. G Remuzzi reports consulting fees from Janssen, Otsuka Pharmaceuticals, Boehringher Ingheleim, Menarini Ricerche, BioCryst Pharmaceuticals, Alexion Pharmaceuticals; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma as external expert: co-chair and speaker 59th ERA congress, and from AstraZeneca Pharmaceuticals; participation on a Data Safety Monitoring Board or Advisory Board from Silence Therapeutics, Omerois Corporation, and Alexion Pharmaceuticals; all outside the submitted work. A Riad reports grants and contracts from the Ministry of Education, Youth and Sports of the Czech Republic (MŠMT) "Systemic Risk Institute (SYRI) Project Number: LX22NPO5101", from Masaryk University "MUNI/A/1402/2021", and from Masaryk University "MUNI/IGA/1104/2021", all outside the submitted work. S Sacco reports grants or contracts from Novartis, and Uriach; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Allergan-Abbvie, Abbott, Teva, Novartis, Lilly, Novonordisk, Pfizer, and Lundbeck; support for attending meetings and/or travel from Lilly, and Lundbeck; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as President elect European Stroke Organisation, and Second vice president European headache Federation; receipt of equipment, materials, drugs, medical writing, gifts or other services from NovoNordisk; all outside the submitted work. N Scarmeas reports grants or contracts from EPAD as funding to their institution, and from NovoNordisk as funding to their institution; Participation as Chair of Data Safety Monitoring Board with the Albert Einstein College of Medicine funded by the NIH; outside the submitted work. V Shivarov reports one pending Bulgarian patent; stock or stock options in RSU from ICON plc; and other financial interest from PRAHS/ICON plc as salary; all outside the submitted work. ST Skou reports grants or contracts from the European Research Council as payment to their university, from the European Union's Horizon 2020 research innovation program (grant agreement No 801790), from the Region Zealand as payment to the hospital, program grant from Region Zealand (Exercise First); royalties from Munksgaard and TrustMe-Ed; payment or honoraria for one online presentations, from Nestlé Health Science; participation on as an Advisory Board Member as UK-based NIHR-funded trial PERFORM: Personalised Exercise-Rehabilitation FOR people with Multiple long-term conditions (multimorbidity, NIHR 202020); leadership or fiduciary role in other board, society, committee or advocacy group, paid, with JOSPT as associate editor; other non-financial interests as co-founder of GLA:D[®], a not-for profit initiative hosted at University of Southern Denmark aimed at implementing clinical guidelines for osteoarthritis in clinical practice; all outside the submitted. J Sundstrom reports stock or stock options in Anagram kommunikation AB and Symptoms Europe AB, all outside the submitted work. J-D Zeitoun reports consulting fees from AbbVie, Takeda, Johnson & Johnson, and Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Elsa and ALPTIS; stock in in approximately 30 medical startups and LP in 3 investment funds; all outside the submitted work. Other remaining authors do not have any competing interest.

Author details

¹MEDCIDS, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal. ²CINTESIS@RISE, Faculty of Medicine of the University of Porto, 4200–450 Porto, Portugal. ³Public Health Unit, ULS Santo António, Porto, Portugal. ⁴National School of Public Health. Instituto de Salud Carlos III, Madrid, Spain. ⁵Scientific-Tools.Org, Bergamo, Italy. ⁶Department of Public Health, Babeş-Bolyai University, Cluj-Napoca-Napoca, Romania. ⁷RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca-Napoca, Romania. ⁸Department for Exposure Assessment and Environmental Health Indicators, Germany Environment Agency, Berlin, Germany. ⁹Clinic of Social and Family Medicine, School of Medicine, University of Crete, Crete, Greece. ¹⁰Department

of Healthcare, Faculty of Public Health, University of Vlora, Vlora, Albania. ¹¹Independent Researcher, Rome, Italy. ¹²Institute of Gerontological Health Services and Nursing Research, Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany.¹³Centre for Disease Burden, Norwegian Institute of Public Health, Oslo, Norway, ¹⁴Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.¹⁵National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.¹⁶Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands. ¹⁷Department of Health Eco nomics and Social Security, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland. ¹⁸Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy. ¹⁹Research group for Childhood Cancer, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark. ²⁰Medicine School, University of Applied and Environmental Sciences, Bogota, Colombia.²¹Department of International Health, Maastricht University, Care and Public Health Research Institute - CAPHRI, Maastricht, The Netherlands. ²²Department of Non-Communicable Diseases and Injuries, Santé Publique France, Saint-Maurice, France. ²³Department of Medicine, University College Cork, College Road, Cork City, Ireland. ²⁴Department of Geriatric Medicine, Mercy University Hospital, Grenville Place, Cork City, Ireland. ²⁵Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta. ²⁶Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. ²⁷School of Public Health, University College Cork, Cork, Ireland. ²⁸Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.²⁹Department of Translational Physiology, Infectiology and Public Health, Ghent, Belgium.

Received: 31 May 2023 Accepted: 5 April 2024 Published online: 22 May 2024

References

- Nicole Scholz, Members' Research Service. Addressing health inequalities in the European Union, Concepts, action, state of play. Eur Parliamentary Res Serv. 2020. https://doi.org/10.2861/567478.
- Jutz R. Health inequalities in Europe: Does minimum income protection make a difference? Curr Sociol. 2021;69:99–118.
- Costantini AS, Seniori Costantini A, Gallo F, et al. Population health and status of epidemiology in Western European, Balkan and Baltic countries. Int J Epidemiol. 2015;44:300–23.
- Health at a glance: Europe 2020: State of health in the EU cycle. URL https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-aglance-europe-2020_82129230-en. Accessed 30 Apr 2021.
- European Commission. The health status of the European Union narrowing the health gap. Luxembourg: Office for Official Publications of the European Communities; 2003. https://openlibrary.org/books/OL162 54528M/The_health_status_of_the_European_Union.
- Nuyts PAW, Hewer RMF, Kuipers MAG, et al. Youth Access to Cigarettes Across Seven European Countries: A Mixed-Methods Study. Nicotine Tob Res. 2020;22:1989–96.
- Garin N, Koyanagi A, Chatterji S, et al. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. J Gerontol A Biol Sci Med Sci. 2016;71:205–14.
- O'Caoimh R, Galluzzo L, Rodríguez-Laso Á, et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. Ann Ist Super Sanita. 2018;54:226–38.
- Colombo F, García-Goñi M, Schwierz C. Addressing multimorbidity to improve healthcare and economic sustainability. J Comorb. 2016;6:21–7.
- Quality of life indicators health. URL https://ec.europa.eu/eurostat/stati stics-explained/index.php?title=Quality_of_life_indicators_-_health& oldid=566497 Accessed 5 July 2022.
- Santos JV, Lobo M, Neiva RM, et al. European Union state of health from 1990 to 2017: time trends and its enlargements' effects. Int J Public Health. 2020;65:175–86.
- Boncz I, Vajda R, Ágoston I, Endrei D, Sebestyén A. Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010. Eur J Health Econ. 2014;15(Suppl 1):S137–41.

- Santos JV, Souza J, Valente J, et al. The state of health in the European Union (EU-28) in 2017: an analysis of the burden of diseases and injuries. Eur J Public Health. 2020;30:573–8.
- GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1160–203.
- Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22.
- 16. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223–49.
- 17. GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. Lancet. 2020;396:1135–59.
- Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr. 2012;10:1.
- Martinez R, Soliz P, Caixeta R, Ordunez P. Reflection on modern methods: years of life lost due to premature mortality—a versatile and comprehensive measure for monitoring non-communicable disease mortality. Int J Epidemiol. 2019;48:1367–76.
- Global Health Data Exchange (GHDx). 2014.URL http://www.healthdata. org/about/ghdx. Accessed 30 Apr 2021.
- GBD Compare. 2014.URL http://www.healthdata.org/data-visualization/ gbd-compare. Accessed 30 Apr 2021.
- R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. https://www.Rproject.org/.
- Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388:e19-23.
- Vandenberghe D, Albrecht J. The financial burden of non-communicable diseases in the European Union: a systematic review. Eur J Public Health. 2020;30:833–9.
- 25. Wang Y, Wang J. Modelling and prediction of global non-communicable diseases. BMC Public Health. 2020;20:822.
- Iburg KM, Charalampous P, Allebeck P, et al. Burden of disease among older adults in Europe-trends in mortality and disability, 1990–2019. Eur J Public Health. 2023;33(1):121–6.
- 27. Yang X, Chen H, Sang S, Chen H, Li L, Yang X, Burden of All Cancers Along With Attributable Risk Factors in China From, to 2019: Comparison With Japan, European Union, and USA. Front Public Health. 1990;2022:10. https://doi.org/10.3389/fpubh.2022.862165.
- Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, Gavin A, Flego M, Neamtiu L, Dimitrova N, Negrão Carvalho R, Ferlay J, Bettio M. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–47.
- 29 Bozhar H, McKee M, Spadea T, Veerus P, Heinävaara S, Anttila A, Senore C, Zielonke N, van Ravesteyn NT, Lansdorp-Vogelaar I, de Koning HJ, Heijnsdijk EAM. EU-TOPIA consortium. Socio-economic inequality of utilization of cancer testing in Europe: A cross-sectional study. Prev Med Rep. 2022;26:101733.
- Sørensen HT, Bredahl Kristensen FP. Cardiovascular diseases and health inequalities in Europe-a pressing public health challenge. Lancet Reg Health Eur. 2023;4(33):100722.
- Castelpietra G, Knudsen AKS, Agardh EE, et al. The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019. Lancet Reg Health Eur. 2022;1(16):100341.
- Stumbrys D, Jasilionis D, Pūras D. The burden of mental health-related mortality in the Baltic States in 2007–2018. BMC Public Health. 2022;22(1):1776.
- van de Laar MJ, Likatavicius G. HIV and AIDS in the European Union, 2008. Euro Surveill. 2009;14(47):19422.
- GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019;6:e831-59.

- Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27.
- COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic, Lancet. 2021;398:1700–12.
- Launch of new WHO Mental Health Report: Transforming mental health for all. https://www.who.int/news-room/events/detail/2022/06/17/defau lt-calendar/launch-of-new-who-mental-health-report--transformingmental-health-for-all. Accessed 2 Jun 2022.
- Wyper GMA, Grant I, Fletcher E, Chalmers N, McCartney G, Stockton DL. Prioritising the development of severity distributions in burden of disease studies for countries in the European region. Arch Public Health. 2020;78:3.
- Fahy N, Hervey T, Greer S, et al. How will Brexit affect health services in the UK? An updated evaluation. Lancet. 2019;393:949–58.
- 40. Wyper GMA, Grant I, Fletcher E, McCartney G, Fischbacher C, Stockton DL. How do world and European standard populations impact burden of disease studies? A case study of disability-adjusted life years (DALYs) in Scotland. Arch Public Health. 2020;78:1.
- Park J-H, Eum J-H, Bold B, Cheong H-K. Burden of disease due to dementia in the elderly population of Korea: present and future. BMC Public Health. 2013;13:293.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.